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Pharmacologically active compounds in the environment and their chirality 
Barbara Kasprzyk-Hordern
*
 
University of Bath, Department of Chemistry, Faculty of Science, Bath BA2 7AY, UK  
Abstract 
Pharmacologically active compounds including both legally used pharmaceuticals and illicit drugs 
are potent environmental contaminants. Extensive research has been undertaken over the recent 
years to understand their environmental fate and toxicity. The one very important phenomenon that 
has been overlooked by environmental researchers studying the fate of pharmacologically active 
compounds in the environment is their chirality. Chiral drugs can exist in the form of enantiomers, 
which have similar physicochemical properties but differ in their biological properties such as 
distribution, metabolism and excretion, as these processes (due to stereospecific interactions of 
enantiomers with biological systems) usually favour one enantiomer over the other. Additionally, 
due to different pharmacological activity, enantiomers of chiral drugs can differ in toxicity. 
Furthermore, degradation of chiral drugs during wastewater treatment and in the environment can 
be stereoselective and can lead to chiral products of varied toxicity. The distribution of different 
enantiomers of the same chiral drug in the aquatic environment and biota can also be 
stereoselective. Biological processes can lead to stereoselective enrichment or depletion of the 
enantiomeric composition of chiral drugs. As a result the very same drug might reveal different 
activity and toxicity and this will depend on its origin and exposure to several factors governing its 
fate in the environment.  
In this review a discussion of the importance of chirality of pharmacologically active compounds in 
the environmental context is undertaken and suggestions for directions in further research are made. 
Several groups of chiral drugs of major environmental relevance are discussed and their 
pharmacological action and disposition in the body is also outlined as it is a key factor in 
developing a full understanding of their environmental occurrence, fate and toxicity. 
This review will be of interest to environmental scientists, especially those interested in issues 
associated with environmental contamination with pharmacologically active compounds and chiral 
pollutants. As the review will outline current state of knowledge on chiral drugs, it will be of value 
to anyone interested in the phenomenon of chirality, chiral drugs, their stereoselective disposition in 
the body and environmental fate.  
Keywords: chirality, chiral drugs, pharmaceuticals, illicit drugs, environment 
1. Introduction 
Pharmacologically active compounds that include both legally used pharmaceuticals and illicit 
drugs are a group of emerging environmental contaminants, potentially hazardous compounds that 
have been receiving steadily growing attention over the last decade. Surprisingly, there are limited 
data and minimal understanding of the environmental occurrence, transport, fate and exposure for 
many pharmaceuticals and their metabolites, despite their frequently high annual usage
1-4
. Some of 
the most commonly used pharmaceuticals are sold in the UK in hundreds of tonnes per year. Usage 
of drugs is going to increase in the future due to the ageing population in western countries and an 
increase in consumption levels in the developing world. Illicit drugs, belonging to the same group 
of biologically active compounds, have however hardly been studied in the environment
5-9
. One of 
the reasons for a lack of data was, until recently, a lack of suitable analytical methods capable of 
detecting polar compounds at very low concentrations in a complex environmental matrix. 
However, due to increasing concern regarding the possible effect of pharmaceuticals on humans and 
wildlife, an increase in interest in the environmental occurrence of these compounds is to be 
expected. 
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There is also a general lack of information concerning eco-toxicological data on pharmaceuticals 
and their metabolites. Although the preliminary aquatic risk assessment of pharmaceuticals indicate 
that exposure concentrations are one to two orders of magnitude lower than LOEC (lowest observed 
effect concentration) and NOEC (no observed effect concentration) values suggesting low risk, 
long-term environmental risks associated with the presence of pharmaceuticals are hardly known. 
For example a decline of vulture population in Pakistan due to exposure to low levels of diclofenac 
proves that the presence of pharmaceuticals in the environment cannot be underestimated
10
. 
Therefore, when discussing toxicity results obtained with traditional toxicity testing procedures 
such as lethality, growth and reproduction, it is important to consider that these results do not 
represent the true potential hazard of pharmacologically active compounds in the environment, due 
to the duration of these procedures versus actual environmental exposure 
The aim of this review is to outline the state of knowledge and future research directions concerning 
environmentally relevant pharmacologically active compounds which reveal chiral nature. Several 
themes are discussed: 
- Sources, distribution and occurrence of pharmacologically active compounds in the 
environment. 
- Principles of chirality and its importance in the disposition of chiral drugs in humans. 
- Current state of knowledge concerning occurrence, fate and toxicity of chiral drugs in the 
environment. 
- Review of major groups of chiral drugs of environmental concern including their 
pharmacokinetics and environmental fate and toxicity.  
This review is written by an environmental chemist and directed mainly at environmental scientists 
and therefore only certain aspects of pharmacological action and disposition of chiral drugs in the 
body relevant to the environmental field are outlined as they are key factors in developing a full 
understanding of environmental occurrence, fate and toxicity of chiral drugs.  
2. Pharmacologically active compounds in the environment 
2.1. Sources and distribution of pharmaceuticals and illicit drugs in the environment  
Pharmaceuticals and illicit drugs enter the aquatic environment mainly through treated (or raw) 
sewage from domestic households and hospitals, waste effluents from manufacturing processes and 
runoff. Domestic animals are the main direct source of the environmental disposal of many 
veterinary pharmaceuticals (antibiotics, anaesthetics, etc), as manure is very often applied to 
agricultural fields as a fertiliser. Sludge from wastewater plants containing human pharmaceuticals 
(especially those of more hydrophobic nature) is also used as fertiliser in agricultural fields or 
transported to landfill. Pharmaceuticals might enter the aqueous environment as parent unaltered 
compounds, metabolites, conjugates, or might undergo transformation during wastewater treatment 
to produce compounds of significant concern to humans and wildlife. Many of these compounds are 
ubiquitous and persistent in the environment. Additionally, they are continuously introduced into 
the environment; therefore even compounds of a low persistence might cause adverse effects. The 
other issue is the synergistic effect of different pharmaceuticals on organisms, through their 
combined parallel action. Due to their very often polar and non-volatile nature, many 
pharmaceuticals will not undergo volatilisation from the aqueous environment, which extends the 
exposure of aquatic organisms to these compounds. Aquatic organisms are an obvious primary 
target. However, the terrestrial environment is also at risk
1, 2, 11, 12
. Pharmaceuticals have been also 
detected in drinking water, which poses a direct risk to humans
2
 and raises the issue of 
contaminated water sources and especially water reuse.   
2.2. Occurrence of pharmaceuticals and illicit drugs in the environment  
Pharmaceuticals represent a versatile group of compounds, which are found in surface waters at the 
levels of up to a few μg L-1 1, 2, 8, 9, 13-15. Thousands of pharmaceuticals are approved for human or 
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veterinary usage, although only a very small percentage of these compounds have been studied for 
presence in the environment (about 80-150 pharmaceuticals)
2, 16
, not to mention their active 
metabolites and degradation products. Antibiotics, steroid compounds and analgesics/anti-
inflammatory drugs are the most widely studied pharmaceuticals. These compounds are widely 
used not only in human therapy but also in animal treatment. A huge percentage of antibiotics such 
as doxycycline, oxytetracycline and levofloxacin is excreted by the human body unchanged. 
Moreover, due to their direct influence on the natural microbiota and the formation of resistant 
strains, the risk concerning their usage is significant
1, 4, 13, 16
. Anti-inflammatories (diclofenac, 
ibuprofen, naproxen, ketoprofen), blood lipid regulators and their metabolites (gemfibrozil and 
clofibric acid) were recently found to be toxic in respect of certain bacteria and algae
13
. 
Additionally, some of them, such as diclofenac, are poorly removed by WWTP (wastewater 
treatment plant), ubiquitous and persistent in the environment
1, 9
. Antiepileptic drugs are also 
ubiquitous, poorly removed in WWTP and toxic to bacteria and algae
1,18
. Carbamazepine has been 
widely detected in the environment, even if excreted at a low percentage as an unchanged drug 
(3%)
1, 2, 8, 9
.  
For several groups of pharmaceuticals of a very high usage, there is little or no data on their 
presence and fate in the environment and effects on non-targeted organisms. These are for example 
central nervous system drugs such as: antipsychotic drugs, antidepressants or sedative drugs which 
are distributed in huge quantities across the world. For example popular antidepressants such as 
venlafaxine, fluoxetine or citalopram are prescribed in England in tens of tonnes annually
19
. 
Surprisingly, despite their possible physiologic effect on non-targeted aqueous organisms, their 
presence has not been widely analysed in the environment. Antineoplastics used in hospitals as 
chemotherapy agents are suspected of potential mutagenic, teratogenic or carcinogenic effects on 
non-targeted aqueous organisms. Some, such as phosphamide, are poorly removed from WWTP, 
although there is minimal knowledge about their overall stability during wastewater treatment and 
their fate in the environment
1
.  
Illicit drugs have also hardly been studied in the environment and only a few reports have been 
published on the occurrence of these compounds in surface water and/or wastewater. Investigations 
have taken place in the following countries: Italy
5, 20
, Spain
21-24
, Ireland
25
, UK
5, 8, 9
, Belgium
7
, 
Switzerland
26
 and the USA
27-29
. Due to the limited extent of research undertaken in this field, there 
is minimal understanding of the environmental occurrence, transport, fate and exposure for these 
compounds and their very often active metabolites. There is also no information available on the 
ecotoxicity of illicit drugs and their metabolites. Although illicit drugs are present in the aquatic 
environment at low ppt levels, their possible effect on living organisms cannot be overestimated. 
This is because illicit drugs reveal very high pharmacological potency in humans at very low levels. 
For example, LSD is among the most potent drugs known, being active in humans at doses from 
about 20 µg
30
. 
Although several projects concerning the presence and fate of pharmaceuticals have been carried 
out across the world in recent years they have usually concentrated on a limited number of 
pharmaceuticals. Additionally, only a very limited, if any, investigation into the presence of their 
metabolites has been undertaken despite the fact that analysis of pharmaceuticals’ transformation 
products is a crucial factor in understanding their fate and effects in the environment, especially 
because many metabolites of pharmaceuticals are biologically active. The verification of 
environmental levels of pharmacologically active compounds and their removal very often does not 
take into consideration conjugated forms of studied drugs, which might result in an underestimation 
of environmental exposure. The one very important phenomenon that was hugely 
overlooked by environmental researchers studying the fate of ph armaceuticals and 
illicit  drugs in the environment is their chirality.   
Lack of interest of environmental researchers in the chirality of drugs is surprising as chirality of 
several other environmental pollutants was widely studied
31-34
. Among them are: phenoxyalkanoic 
acid herbicides, acetamide pesticides, organophosphorous compounds, pyrethroids, polychlorinated 
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biphenyls (PCBs), polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans 
(PCDFs). Biotransformation in animals, degradation, bioaccumulation, and toxicity of these 
compounds are often stereospecific
35
. For example enantioselectivity in microbial mediated 
biotransformation phenoxyalkanoic herbicides such as: mecoprop and dichlorprop (of which only 
R-enantiomer has herbicidal activity) is widely reported. Stereospecific biodegradation of acetamide 
pesticides such as metolachlor and metalaxyl is also understood. Stereospecific toxicokinetics was 
observed in the case of pyrethroids in mammals. Stereoselectivity of chiral metabolites of PCBs, 
PCB-methyl sulphones (MeSO2-PCBs) in mammalian species was also reported. It was observed 
that (+)-fenamiphos (organophosphorous pesticide) was more toxic to daphnids and also dissipated 
from soils faster than its antipode. In the case of racemic ruelene, change in enantioselectivity was 
observed as a result of temperature changes and deforestation, which might have huge implications 
in a changing climate
31, 32
.  
3. Chiral drugs 
3.1. Principles of chirality  
Chirality plays an important role in the life of plants and animals but it is also vital in the 
agricultural, pharmaceutical and chemical industries. All proteins, enzymes and carbohydrates are 
chiral. More than half of the drugs currently in use are chiral compounds and many of these are 
marketed as racemates consisting of an equimolar mixture of two enantiomers. Chiral natural 
compounds, as opposed to many chiral man-made chemicals, exist in one enantiomeric form (e.g. 
amino-acids are l-isomers and natural sugars are d-isomers). Enantiomers of the same drug have 
similar physicochemical properties but differ in their biological properties
36
. Distribution, 
metabolism and excretion in the body usually favour one enantiomer over the other. This results 
from the fact that enantiomers stereoselectively react in biological systems for example with 
enzymes. Plasma protein binding is also stereoselective. Furthermore, biological transformation of 
drugs can be steroselective, so the enantiomeric composition of chiral compounds may be changed. 
Metabolites of achiral compounds can also be chiral (e.g. achiral albendazole or risperidone are 
transformed into chiral metabolites). Additionally, due to different pharmacological activity, chiral 
drugs can differ in toxicity. Thalidomide is an excellent example. As a result of the administration 
of the racemic form of this sedative drug to pregnant woman, thousands of babies were born with 
deformities in 1960s. A therapeutic (+)-enantiomer of thalidomide is harmless (has tranquilising 
properties) but its (-)-enantiomer is teratogenic and leads to malformations of embryos if 
administered to pregnant woman. Furthermore, (+)-enantiomer in the human body undergoes in 
vivo inter-conversion leading to toxic (-)-enantiomer. Therefore even administration of harmless 
(+)-enantiomer might lead to serious consequences.
 
 
Unfortunately, many chiral drugs are still produced as racemate because either their chiral 
separation is difficult, or the cost of their stereoselective synthesis is too high, or simply at the time 
of the discovery of the drug, only racemic mixture was considered in the animal and the clinical 
pharmacology, toxicology and teratology studies and knowledge of pharmacodynamic, 
pharmacokinetic or toxicological properties of individual enantiomers is still limited
37, 38
. 
3.2. Global market 
The phenomenon of chirality is currently a major driving force in drug discovery and development. 
In the past decades chiral drugs were produced mainly as racemates but with the introduction of 
new technologies allowing for the separation of optical isomers an interest in the design and 
distribution of only one active enantiomer significantly increased. The rationale behind 
administration of one active enantiomer only is obvious as it leads to: simplification of the 
interpretation of the basic pharmacology, therapeutic and toxic effects, pharmacokinetic properties 
and the relationship of plasma concentrations to effects. Other advantages include: possibility of 
administration of lower dosages of drugs, reduced drug interactions and toxicity
38-41
.  
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Worldwide sales of chiral drugs in single-enantiomer form continuously increase. However, a 
substantial quantity of chiral drugs is still sold in the racemic form. The worldwide market share of 
single enantiomer form increased from 27% in 1996 to 39% in 2002
39
. Shimazawa et al.
42
 observed 
a similar trend in Japan. Murakami
43
 published the most recent report on chiral synthetic drugs 
launched over the last 20 years. Tab. 1 represents new synthetic drugs introduced worldwide 
between the years 1985 and 2004
43
.  
There is at present a tendency in the pharmaceutical industry to switch from racemates to single 
enantiomers. This is because in 1992 FDA
44
 and in 1994 EU
45
 issued guidelines concerning the 
development of new chiral drugs, which favour the development of single-enantiomer rather than 
racemic form
40, 46, 47
. Among drugs for which a racemic switch was undertaken are: R-verapamil, S-
fluoxetine, S-ketoprofen, R-albuterol, levofloxacin, esoprazole, etc (Tab. 2). It has to be however 
remembered that sometimes racemic switch does not lead to the expected increase of drug potency 
and/or in some cases the single-enantiomer form might be less safe than racemic form of the same 
drug (e.g. fluoxetine, labetalol, propanolol and sotalol). This phenomenon can be explained by 
direct pharmacodynamic or pharmacokinetic competition/interaction between two enantiomers 
which results in the prevention of one enantiomer toxicity by another (e.g. labetalol) or a specific 
protective effect provided by one of the enantiomers in the racemic mixture
40, 46
. Propranolol for 
example was found to show lower beta-blocking activity if introduced as S(-)-enantiomer. This 
suggests that the presence of R(+)-propranolol has the beneficial effect of S(-)-propranolol 
availability
37, 46
. Dilevalol, on the other hand, the beta-blocking stereoisomer of labetalol was 
withdrawn from the market due to its increased hepatoxicity when compared to the racemic 
mixture
38
. Sotalol is another chiral drug that is used as a racemate despite initial trials evaluating the 
usage of only (+)-enantiomer as an anti-arrhythmic agent
38
. Therefore despite considerable interest 
in the usage of only one active enantiomer, many chiral drugs are still used in racemic form. This is 
of great importance and can have huge implications when the environmental fate and ecotoxicity of 
chiral drugs are considered. 
3.3. Chiral drugs in humans 
The phenomenon of chirality exists in all biological systems. Biomacromolecules (e.g. enzymes) 
composed from chiral subunits (e.g. amino acids) are capable of selective recognition and 
transformation of individual stereoisomers of other chiral molecules. Stereoselective interactions of 
biomolecules with chiral molecules are an essential part of all vital biological processes including 
disposition of chiral drugs and their pharmacological activity. Therefore enantiomers of chiral drugs 
have to be treated as independent entities rather than just different forms of the same drug as one 
enantiomer may produce the desired therapeutic activity, while the other might be inactive or 
toxic
36, 38, 40, 41, 48
.  
Chiral drugs produced in their racemic form can be divided into three groups
36, 41, 49
: drugs with 
only one major bioactive enantiomer, drugs with two bioactive enantiomers and drugs with only 
one major bioactive enantiomer but with the potential for the second non-active enantiomer to be 
transformed in the body to its bioactive form through chiral inversion. 
3.3.1. Drugs with only one major bioactive enantiomer  
The majority of chiral drugs belong to this group. These drugs are usually distributed as racemates. 
Among beta-blockers and calcium channel blockers, levorotary isomer is more active than 
dextrorotary isomer (e.g. S(-)-propranolol is 100 times more active than R(+)-propranolol). 
Sympathomimetic drug-selective beta-aderenoceptor antagonists such as sabutamol have l-
enantiomer (R(-)-enantiomer) which is pharmacologically active but d-enantiomer can be 
responsible for some side-effects. In the case of hypnotics such as barbiturates, only their R(-)-
isomer is hypnotic/sedative and S(+)-isomer will be either inactive or excitative (convulsant). R(-)-
methadone is about 25-50 times more potent than S(+)-methadone. On the other hand 
antidepressant S(+)-citalopram is 100 times more potent  than its R(-)-enantiomer. Other chiral 
drugs belonging to this group include: antibiotics (e.g. ofloxacin), anti-inflammatory/analgesics 
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(e.g. ketoprofen) and psycho-stimulants (e.g. amphetamines)
36
. The phenomenon of amphetamine’s 
chirality is crucial in forensic analysis. S(+)-enantiomer of amphetamine is known to be much more 
potent than R(-)-enantiomer and is present in illicitly used amphetamine. On the other hand R(-)-
enantiomer is often present in pharmaceutical preparations and/or excreted as a metabolite of 
certain drugs (e.g. selegiline). 
Drugs with only one major bioactive enantiomer can be divided into two groups: 
 Stereoisomers that have the same quality of action but differ in potency  
Calcium channel blockers distributed in the racemic form belong to this group (with the exception 
of achiral nifedipine, and diltiazem, which is sold in the form of one active cis (+)-stereoisomer). 
These drugs are characterised by quantitative differences in potency, rather then in 
pharmacological effects elicited (e.g. warfarin and verapamil)
49, 50, 53
. For example S-verapamil is 
known to be more potent that R-enantiomer, but both enantiomers do not elicit different 
pharmacological effects (e.g. S-enantiomer is 20 times more potent in exerting negative 
dromotropic effect; 4 times more active in blood pressure reduction and equipotent with R-
verapamil in the case of modulation of P170-mediated multidrug resistance)
49
. Antidepressant S-
citalopram is also characterised by much higher potency than R-enantiomer in the inhibition of 5-
hydroxytryptamine uptake. Therefore S-enantiomer, given the generic name escitalopram, has been 
marketed since 2002
38
. 
 Stereoisomers of which only one is active  
Beta-receptor antagonists have only one active enantiomer. They contain at least one chiral centre 
and with the exception of timolol and penbutolol are administrated as racemates. The beta-blocking 
activity of S-enantiomer is at least two times higher for most beta-blockers than that of R-
enantiomers
49
. 
3.3.2. Drugs with two enantiomers which are equally biologically active  
This group includes only some drugs such as cyclophosphamide (antineoplastic) and fluoxetine 
(antidepressant)
36
. This group of enantiomers can be divided into two main subgroups: 
 Stereoisomers that are equipotent 
Enantiomers of antiarrhythmic drugs (flecainide, mexiletine, tocainide, propafenone) and 
antimalarials (mefloquine, halofantrine, enpiroline) have small or no differences in their potency
49
.  
 Stereoisomers that are both active but have qualitatively different actions 
To this group belong chiral drugs with enantiomers being agonists at different receptors (e.g. 
dobutamine: (+)-enantiomer has β-blocking agonist activity, while (-)-enantiomer has α-blocking 
agonist activity), antagonists at different receptor (e.g. labetalol, beta-adrenoceptor antagonist 
having two chiral centres and four stereoisomers: R,R-enantiomer has β-blocking antagonist activity 
and S,R-enantiomers has α-blocking antagonist activity) and rarely agonists and antagonists at the 
same receptor (e.g. 1,4-dihydropyridines: one enantiomer behaves as calcium channel antagonist 
and the other one as calcium channel agonist)
49, 52. Also enantiomers of α-propoxyphene differ in 
pharmacological actions. Whereas (+)-enantiomer is a potent analgesic, (-)-enantiomer is a potent 
antitussive agent
49, 53
. Some barbiturates also belong to this group. While R(-)-enantiomers are 
general anaesthetics, S(+)-enantiomers may be convulsant
48
. Also ketamine, an often abused 
anaesthetic, is more potent and less toxic in its S(+)-isomer form. S(+)-Ketamine is anaesthetic and 
analgesic, whereas R(-)-ketamine produces undesirable side effects such as hallucination and 
agitation
53
. The already mentioned thalidomide also belongs to this group. Other examples include: 
antiarthritic agent penicillamine (S-enantiomer has pharmacological action while R-enantiomer is 
extremely toxic) and the antitubercular agent ethambutol (S,S-enantiomer is an active 
tuberculostatic while R,R-enantiomer causes optical neuritis that can result in blindness). L-dopa, 
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used for treatment of Parkinson’s disease, is marketed as single enantiomer because of the serious 
side-effects of D-isomer such as granulocytopenia
54
. 
3.3.3. Drugs with only one major bioactive enantiomer but with potential for the second non-active 
enantiomer to be transformed in body to its bioactive form through chiral inversion 
Nonsteroidal anti-inflammatory drugs (ibuprofen, ketoprofen, etc) have an active S-enantiomer (e.g. 
S-ibuprofen is over 100 times more potent than R-ibuprofen). They can undergo enzyme mediated 
unidirectional inversion, which indicates that only an inactive R-enantiomer can undergo inversion 
into an active S-enantiomer. Benzodiazepines (d-enantiomer more potent than l-enantiomer) and 
thalidomide on the other hand undergo bidirectional chiral inversion or racemisation, which means 
that both R and S enantiomers can racemise in vitro by aqueous solution
36, 55, 56
.  
It has to be however emphasised here that different degrees of stereoselectivity can be observed for 
the same chiral drug regarding different effects as the stereoselective behaviour of chiral drugs is 
directly dependent on their modes of interaction with the macromolecules involved in eliciting 
certain pharmacological effects. For example, the decrease in heart rate mediated by beta-
adrenoceptor antagonists is highly stereoselective for the S-enantiomer, while no enantioselectivity 
is observed for the local anaesthetic effects
49
. Furthermore, stereoselective disposition of drugs is 
also species dependant and as a result its understanding is of the greatest importance in 
understanding the environmental fate and ecotoxicity of chiral drugs. 
3.4. Disposition of chiral drugs in humans 
After administration a chiral drug is subject to a variety of physiological processes such as 
absorption, distribution, metabolism and excretion. Many of these processes are stereoselective as 
they involve an interaction between chiral drugs and chiral biological macromolecules
37, 38, 49
. 
3.4.1. Absorption, distribution and elimination 
Drugs are usually absorbed by passive diffusion. As enantiomers do not differ in their 
physicochemical properties (lipophilicity, ionisation, molecular size), absorption is not usually 
considered to be a stereoselective process. However, stereoselectivity is expected and has been 
observed for drugs that are transported by a carrier-mediated process such as facilitated diffusion or 
active transport
37, 38, 49, 52, 57, 58
. Stereoselective transport of chiral drugs across the skin should also 
be mentioned here due to the possible effect it might have in terms of human exposure to chiral 
environmental contaminants. For chiral drugs with the biological activity associated with only one 
enantiomer, enantioselective permeation can for example affect the pharmacodynamic profile of the 
racemate. Although there is only limited information on the skin’s stereoselective permeation, 
metabolism and binding, it has been established that stereoselectivity is observed in the case of 
some drugs (e.g. propranolol’s transport through rat’s skin)59. 
Furthermore, the distribution of chiral drugs in the body might be stereoselective as binding of 
chiral drugs to plasma or tissue proteins, and also transport via specific tissue, uptake and storage 
mechanisms can be stereoselective. As the drug in plasma that is not bound to proteins is 
responsible for pharmacological activity, differences in binding of enantiomers to proteins will 
affect their active concentration at the site of action. Competition between the pair of enantiomers 
for the same protein binding sites can also lead to higher free fractions of one enantiomer if the drug 
is administered in the racemic form. This might subsequently lead to changes in the disposition of 
chiral drugs when administered as racemate or single enantiomeric form. Furthermore, enantiomers 
of chiral metabolites can also stereoselectively bind to plasma proteins
38, 48, 49, 57, 58, 60
.  
The renal elimination of many chiral drugs by glomerular filtration and tubular 
secretion/reabsorption is stereoselective and can be affected by enantiomers’ competitive 
stereoselective interactions with the anion/cation transport proteins in the renal tubular epithelial 
cells. These transporters have restricted capacity and as a result the enantiomers of racemic drugs 
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can compete for these sites potentially altering the disposition of each enantiomer when the 
racemate is given
49, 58, 60
. 
3.4.2. Metabolism 
Stereoselective first-pass metabolism is observed in the case of many drugs and is considered to be 
rather a rule than an exception
38
. Among them are for example calcium channel blockers and beta-
adrenoceptor antagonists e.g. active S-verapamil is more readily metabolised than R-enantiomer. 
Bioavailability of active S-propanolol is 1.5 times higher than its R-enantiomer also due to 
stereoselective first-pass metabolism
49
. 
Stereoselectivity of drugs metabolism can result from differences in the binding of chiral drugs to 
the enzyme active site and/or to catalytic sites. As a result two enantiomers of the same drug can be 
metabolised at different rates (by the same enzymes, e.g. verapamil) or via different routes (by 
different enzymes, e.g. warfarin and mephenytoin) and can lead to different products
38, 50
. There are 
several factors that might affect stereoselective metabolism. Among them are: disease, drugs 
interactions, ethnic differences, sex, age and lifestyle
52, 58, 60
. Significant consequences (inhibition or 
induction) of stereoselective metabolism might be observed in the case of two enantiomers, which 
differ in potency
49, 57
. Drugs interactions are also important. In the case when a pair of enantiomers 
is metabolised by different enzymes, a co-administered drug might inhibit the metabolism of one 
enantiomer only and not affect (or accelerate) the metabolism of the second enantiomer. If the 
metabolism of a more potent enantiomer is inhibited, this will obviously result in an increase of the 
drug’s activity. On the other hand if inhibition of the not active enantiomer takes place, the opposite 
situation will be observed. Transport into bile and biliary elimination can be also stereoselective
49, 
50, 61
. 
It should be also emphasised here that interspecies differences in the stereoselectivity of metabolism 
are very common. For example the metabolic oxidation of felodipine is greater for the S-enantiomer 
in humans, whereas a preferential metabolism of R-enantiomer takes place in rats and dogs
58
. 
Significant species differences exist in enantioselective pharmacokinetics for several drugs such as 
propranolol and warfarin where clearance shows the opposite stereoselectivity in animals compared 
to humans (propranolol: S>R in dog and R>S in humans; warfarin: R>S in rats and S>R in 
humans)
60
. The hydrolysis of esmolol also shows no stereoselectivity in human but in the case of 
dog and rat blood (-)-isomer is hydrolysed faster. On the other hand (+)-esmolol is hydrolysed 
faster in monkey, rat and guinea-pig blood
60
. Significant species difference is also observed in the 
case of chiral inversion of 2-aryl propionic acids
60
. 
Enantiomers of chiral drugs can be metabolised at different rates (leading to quantitative 
differences) or by different routes (leading to qualitative differences) resulting in preferential 
metabolism of one enantiomer as enzymes are chiral in nature
37, 49, 61
. In the case of warfarin both 
different rates and different routes are observed (Fig. 1).  
Chiral drugs can be metabolised while retaining the same chiral centre in parent compound and 
metabolite, with an introduction of another chiral centre or the removal of chiral centre from the 
chiral molecule. In the first case, if the functional groups remain unaltered the absolute 
configuration of the parent compound and the metabolite will be the same, although the rate of 
biotransformation of each enantiomer can differ and the enantiomeric ratio of the chiral metabolite 
will also differ from that of the parent compound
49
. For example, S-warfarin undergoes aromatic 
oxidation with the formation of S-7-hydroxy-warfarin and S-6-hydroxywarfarin
38
. Such retention of 
stereoselectivity of the parent compound and metabolite is vital in the identification of the 
stereochemical form of the drug administered. This phenomenon is also utilised in forensic 
identification of illicitly used amphetamine where differentiation between legal and illicit usage of 
amphetamine can be estimated only through the analysis of enantiomeric ratios of excreted 
amphetamine. S-(+)-enantiomer of amphetamine is known to be much more potent than R-(-)-
enantiomer and is present in illicitly used amphetamine either in pure or racemic form. On the other 
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hand R-(-)-enantiomer is often present in pharmaceutical preparations and/or excreted as a 
metabolite of certain drugs (e.g. selegiline) (Fig. 2). 
Biotransformation of chiral drugs might also lead to the introduction of another chiral centre into a 
chiral molecule leading to the formation of diastereoisomers
49
. Among chiral drugs metabolised 
with the formation of additional chiral centre are: thioridazine (Fig. 3), metoprolol and bufuralol. 
The stereoselective glucuronidation of oxazepam, keto-reduction of warfarin also lead to the 
formation of diastereoisomeric derivatives
38, 62
.  
Metabolism can also lead to the removal of chiral centre from the chiral molecule. This process is 
characteristic for chiral calcium antagonists with dihydropyridine structure (e.g. nilvadipine) where 
oxidation of the dihydropyridine ring to the corresponding pyridine analogue leads to the loss of 
chirality. Oxidation of the benzimidazole proton pump inhibitors (e.g. omeprazole) at the chiral 
sulphoxide also leads to achiral sulphone (Fig. 4)
 38, 49
. Deamination of amphetamine to yield 
phenylacetone also leads to the removal of chiral centre
63
.  
Some chiral drugs can undergo enzymatic chiral inversion, which results in the inversion of one 
enantiomer into the second one. This phenomenon is observed for non-steroidal anti-inflammatory 
2-arylpropoinic acid derivatives such as: ibuprofen, benoxaprofen, cicloprofen, fenoprofen, 
flurbiprofen, ketoprofen and thioxaprofen, in which case chiral inversion of less potent R-
enantiomer to the more potent S-enantiomers takes place. As a result of chiral inversion, despite 
revealing much higher potency of S-enantiomer in vitro, a significant decrease of such potency is 
observed in vivo. This is because not active R-enantiomer is a subject of inversion into more potent 
S-enantiomer. For example S-ibuprofen is 160 times more potent that R-ibuprofen in vitro, but only 
1.4 times more potent in vivo (Fig. 5)
 38, 48, 49, 56, 64
. Chiral inversion of NSAIDs takes place as a 
result of conjugation through a Coenzyme A (CoA) thioester intermediate. It is also worth 
emphasising that inversion by conjugation in other xenobiotic enantiomers can take place through 
other conjugation mechanisms such as glutathione. It has to be also noted here that metabolic chiral 
inversion of chiral drugs might be species dependant. For example R-flurbiprofen undergoes 
inversion in dogs and guinea pigs, but is negligible in rats and humans. Ketoprofen undergoes 
significant inversion in rats, dogs and horses (74-92%) with the smallest conversion in gerbils 
(27%) and humans (~10%). Microorganisms are also capable of chiral inversion. For example 
Verticillum lecanii inverts R-ibuprofen, fenoprofen and suprofen
56
. 
Finally, metabolic interactions between enantiomers of chiral drugs, leading to different disposition 
of chiral drugs when administered as racemate can be observed. The two enantiomers of the same 
drug can either compete for metabolism at the catalytic site of the same enzyme or one enantiomer 
can inhibit the enzyme for which the second enantiomer is a substrate. Such a phenomenon is 
observed in humans and animals in the case of several drugs such as: propafenone, nitredipine, 
propranolol, amphetamine, propoxyphene and warfarin
49
. The above has crucial implications in the 
decision making process of whether the distribution of chiral drugs as racemate or single 
enantiomer should be implemented. 
It is also worth mentioning that metabolism of achiral drugs can lead to the formation of chiral 
metabolites through the introduction of a chiral centre
49, 63
. Among achiral drugs being metabolised 
to chiral metabolites are: haloperidol (antipsychotic), phenytoin (antiepileptic), debrisoquine 
(antihypertensive), cimetidine (H2-receptor antagonist), risperidone (antipsychotic) and some 
benzimidazoles (extensively used also in veterinary treatment) such as fenbendazole and 
albendazole
38, 48, 62, 63, 65
. Sulphide benzimidazoles are prochiral drugs and are used as anthelmintics. 
They are metabolised primarily to sulphoxides (active) and then to sulphones (not active). 
Sulphoxides are chiral and are responsible for most of the therapeutic activity (Fig. 6)
48, 66
. 
Sulphoxidation of cimetidine leads preferentially to the (+)-enantiomer of cimetidine sulphoxides
62
. 
Achiral phenytoin is metabolised to chiral 5-(4-hydroxyphenyl)-5-phenylhydantoin
67
. 9-
Hydroxylation of risperidone and the metabolic formation of reduced haloperidol from haloperidol 
result in the formation of metabolites with chiral centres as presented in Fig. 6
65
.  
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Due to stereoselective metabolism of chiral drugs and stereoselective formation of active 
intermediates and metabolites, the toxicity of enantiomers might also significantly differ
61
. For 
example the urotoxicity of racemic ifosfamide is caused by acrolein which is a breakthrough 
product of stereoselective dechloroethylation
49, 58
. Also in the case of male antifertility agents (3-
chloropropane-1,2-diol and 3-amino-1-chloropropane-2-ol) studied on rats, only S-enantiomer 
revealed the antifertility activity while R-enantiomer is associated with nephrotoxicity due to its 
metabolism to R-3-chlorolactate leading to the formation of toxic 3-chloropyruvate
38
. The already 
mentioned S(-)-thalidomide is teratogenic as opposed to its sedative R(+)-enantiomer. Alitretinoin 
(9-cis-retinoic acid) and isotretinoin (13-cis-retinoic acid) are isomers of tretinoin all-trans retinoic 
acid. Their teratogenic effects are thought to be mediated as a result of their transformation to all-
trans retinoic acid. Chiral structural analogues of valproic acid (VPA): 4-yn-VPA and 4-en-VPA are 
chiral and have varying teratogenic potential: R(+)-4-yn-VPA<R(+)-4-en-VPA<VPA<S(-)-4-en-
VPA<S(-)-4-yn-VPA
35, 67
.  
The above discussion indicates that disposition of chiral drugs in the body is a very complex and 
often highly stereoselective process, which is potentially influenced by several parameters. Its 
understanding is therefore vital in informed decision making process concerning the administration 
of chiral drugs to humans and its possible consequences. It is also essential as far as environmental 
issues associated with the presence of chiral drugs in the environment are concerned, as chiral 
molecules are also subject to several complex and often stereoselective biological processes taking 
place in the environment, which might influence (often alter) the overall fate and ecotoxicity of 
these compounds. Unfortunately, only scarce information exists in the literature regarding the 
stereoselective fate and toxicity of chiral drugs in the environment. The following paragraph 
represents a short overview of current knowledge on chiral drugs in the environment. 
4. Chiral drugs in the environment 
4.1. Enantioselective drug analysis in environmental samples 
Analysis of drugs at trace ppt concentrations in very complex environmental matrices poses a 
significant analytical challenge mainly due to problems associated with their separation from other 
interfering polar compounds. The above requires the application of sensitive analytical methods 
such as chromatography coupled with tandem mass spectrometry and combined with sample 
concentration/clean-up. Separation of enantiomers of drugs is even more problematic as traditional 
chromatography does not provide high enough selectivity to differentiate between enantiomers of 
the same compound. The development of robust methods for the separation of enantiomers of chiral 
compounds is therefore vital in the understanding of their occurrence and fate in the environment. 
Additionally, the establishment of multi-residue methods is crucial to obtain information regarding 
the cumulative presence of several groups of analytes at a particular place and time. This is of great 
importance as synergistic effects of different drugs on aquatic life might take place and have to be 
investigated. It has already been verified that acute toxicity of a group of pharmaceuticals can be 
higher than for individual pharmaceuticals. Although a few research groups have attempted to 
analyse single chiral drugs in environmental samples (Tab. 3), to date there are no multi-residue 
methods for the analysis of chiral drugs in environmental matrices. 
On the other hand, extensive development of enantioselective analysis has taken place over the 
recent two decades in response to demand in drug development field for efficient technologies 
utilised in the preparation of enantiomerically pure compounds and quality control of these 
processes. Among the most popular separation techniques used for enantiomer analysis are liquid 
chromatography, followed by capillary electrophoresis and gas chromatography. Due to the 
limitations of space it is not possible to include full details on chiral separation techniques. The 
reader is therefore advised to seek more detailed information elsewhere. A few comprehensive 
books/book chapters
33, 34,
 
68-71
 and reviews
51, 72-78
 were published in this field in the recent few 
years.  
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Despite the availability of methods for chiral analysis of drugs in biological matrices it is difficult to 
directly utilise them in trace analysis of chiral drugs in the environment. This is because LC/UV is 
usually utilised in the chiral analysis of drugs in biological matrices and it is not sensitive and 
selective enough to be applied in environmental analysis, where usually tandem mass spectrometry 
has to be used. Direct transfer of chiral-LC/UV method to LC/MS/MS method is also not always 
possible because the first one usually uses mobile phases which are incompatible with MS 
applications (non-volatile buffers, normal-phase solvents). Additionally chiral drugs are usually of 
polar nature and therefore if chiral GC is to be used, a derivatisation step has to be undertaken 
before the analysis
31, 79, 80
. Therefore, although challenging, an extensive research in the field of 
chiral separation in complex environmental matrices is required in order to undertake research 
aiming at understanding the fate and toxicity of chiral drugs in the environment. 
4.2. Occurrence, fate and toxicity of chiral drugs in the environment – current knowledge 
4.2.1. Understanding environmental fate of chiral drugs 
Chiral drugs are introduced into the environment as a result of human actions. Before they reach 
environmental matrices they are subjected to both biotic and abiotic processes (Fig. 7). Enantiomers 
of chiral drugs can be characterised by different biological fates in the environment because their 
interaction with chiral entities (e.g. enzymes, biological receptors) can be stereoselective
31
. On the 
other hand abiotic environmental processes (such as sorption, photochemical transformation, air-
water, soil-air exchange) are not stereoselective because enantiomers of the same drug do not differ 
in physicochemical properties. Therefore stereoisomers can serve as markers of biological activity 
in the environment and can be an important source of information regarding biochemical fate of 
chiral compounds in the environment, which is required for accurate risk assessment of these 
pollutants
31, 79
. 
As a result of stereoselective biodegradation of chiral pollutants in the environment (and also during 
wastewater treatment) chiral products of varied toxicity can be formed. For example, γ- 
hexachlorocyclohexane is an achiral pesticide, but it degrades into chiral and toxic γ-
pentachlorocyclohexene
33
. Enantioselective toxic effects are observed in the case of several chiral 
pollutants e.g. (+)-fipronil (phenylpyrazole pesticide) shows a significantly greater reduction in the 
number of off-spring of Daphnia magna than (-)-enantiomer
81
. Distribution of different enantiomers 
of the same pharmaceutical in the aquatic environment and biota can also be stereospecific. 
Therefore, the enantiomeric composition of chiral drugs can change significantly after its 
administration, followed by metabolism in and excretion from the human or animal body. It can be 
subsequently altered during biological wastewater treatment and as a result of biological 
degradation processes in the environment. Biological processes can lead to stereoselective 
enrichment or depletion of enantiomeric composition of chiral drugs. Therefore the very same drug 
might reveal different activity and toxicity and this will depend on its origin and exposure to several 
factors governing its fate in the environment.  
Despite growing, but still limited, knowledge on the environmental fate of chiral pollutants such as 
agrochemicals (phenoxyalkanoic acid herbicides, acetamide and organophosphorous and pyrethroid 
insecticides), polychlorinated biphenyls and their metabolites, and synthetic polycyclic musks (see 
reviews by Wong
31
, Müller and Kohler
32
, Hühnerfuss and Shah
81
) no comprehensive research has 
been undertaken in the field of chiral drugs. Existing reports on the presence and fate of 
pharmaceuticals, due to their non-enantiospecific analysis, do not tackle the problem of their 
chirality, so these studies cannot differentiate between different biological (enantioselective: 
microbial transformation processes, enzymatic transformation) and abiotic (non-enantioselective: 
photochemical transformation) transformation processes to which chiral drugs are exposed. As a 
result, current knowledge of chiral pollutants, especially drugs, is inaccurate, as it incorrectly 
assumes that enantiomers have identical environmental behaviour
31
. 
Therefore to understand and predict the mechanisms governing the fate of chiral drugs, their 
possible toxicity and impact on the environment, determination of their enantiomeric composition 
 12 
in environmental matrices is essential. As only a few reports exist on the analysis of chiral 
pharmaceuticals (beta-blockers, no metabolites) in the environment
82, 83
 and during wastewater 
treatment
79, 84-88
, it is of the greatest importance to investigate this aspect of the presence of drugs in 
the environment.  
The relative concentration of enantiomers of chiral drugs can be expressed as the enantiomeric 
fraction (EF)
83
: 
EF = [enantiomer 1]/([enantiomer 1] + [enantiomer 2]) 
EF equals 1 or 0 in the case of single enantiomer form and 0.5 in the case of racemate. Changes in 
EF for the same chiral drugs can be therefore used to identify enantioselective processes. 
Fono and Sedlak
83
 reported that propranolol was racemic in the influent of studied WWTPs (EF = 
0.49 - 0.54) but not in the effluent wastewater (EF = 0.31 - 0.44) after activated sludge treatment 
(Tab. 4). The highest EF values were observed for WWTP characterised by poor removal during 
secondary biological treatment and during wet weather conditions when 9% of the effluent sample 
consisted of raw sewage that bypassed secondary treatment. It is worth noting here that EF values 
were found to decrease after biological treatment but remained constant after chemical and physical 
treatment (filtration, settling and chlorination), which suggests stereoselective processes occurring 
during biological treatment. Fono et al.
82
 also studied the fate of metoprolol in river. A decrease of 
EF values for metoprolol alongside the river (from EF=0.5 to EF=0.44 over travel time=13 days) 
indicated its biotransformation (Tab. 5).  
Nikolai et al.
79
 studied enantioselective degradation of three β-blockers: atenolol, metoprolol and 
propranolol during wastewater treatment. It was reported that all compounds studied were a subject 
to enantioselective biodegradation (Tab. 4). It was also concluded that this process is season-
dependant and possibly results from changes in populations and selectivity of microbes capable of 
degrading the analyte. Additionally different stereoselectivity was observed in different WWTPs 
suggesting possible different enantioselectivity of biochemical weathering processes
79
. 
MacLeod et al.
84
 studied β-blockers (atenolol, metoprolol, propranolol, pindolol, nadolol and 
sotalol), SSRI (citalopram and fluoxetine) and salbutamol during wastewater treatment and also 
observed changes in EFs of several drugs as a result of wastewater treatment (Tab. 4). Wastewater 
influent was slightly enriched with R(+)-atenolol, while the effluent was racemic. The influent was 
also more enriched with R(-)-fluoxetine than effluent
84
. Unfortunately no studies were undertaken 
for the main active chiral metabolite S(-)-norfluoxetine. An enrichment of fluoxetine with S(-)-
enantiomer as a results of wastewater treatment is of potentially significant toxicological 
consequences as toxic effects of fluoxetine enantiomers are species dependent: S-fluoxetine is more 
toxic than R-fluoxetine in Pimephales promelas, but equal toxicity of both enantiomers in the case 
of Daphnia magna is observed
89
. Propranolol on the other hand was found to be racemic in 
wastewater influent. Effluent in contrast was enriched with S(-)-propranolol, which is known to 
have higher toxicity towards Pimephales promelas than its antipode
84, 89
. MacLeod et al.
87
 
undertook also a several month long monitoring programme of chiral drugs (atenolol, citalopram, 
fluoxetine, metoprolol, nadolol, pindolol, propranolol, salbutamol, sotalol and temazepam) in 
WWTPs’ effluents. With the exception of temazepam, chiral drugs were generally non-racemic. 
Temporal changes in EFs values of studied chiral drugs (with the exception of sotalol) were 
observed and some differences in EFs were also noted among studied WWTPs. It was suggested 
that there might be some variation of microbial transformation of drugs in WWTPs among plants 
and treatment processes. It was however pointed out that temporal differences in enantiomer-
specific metabolism of humans might also contribute to the overall temporal variation in chiral drug 
EFs observed in WWTPs effluents
87
. 
Matamoros et al.
85
 reported that enantioselective degradation of ibuprofen depends on the oxidation 
status of WWTP. In predominantly aerobic conditions S-ibuprofen degrades faster than R-ibuprofen 
(Tab. 4). On the other hand in anaerobic conditions degradation of ibuprofen is not enantioselective. 
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It is suggested that such a situation is a result of the presence of different bacterial consortia under 
aerobic and anaerobic conditions. In contrast EF of naproxen decreased during wastewater 
treatment in the case of both aerobic and anaerobic processes
85
. Different enzymatic metabolisms of 
ibuprofen and formation of the metabolites: hydroxyibuprofen and carboxyibuprofen, encountered 
in the human body, in a sewage treatment plant and in rivers were also observed and reported by 
Hühnerfuss and Shah
81
. Buser et al.
90
 also studied the occurrence and behaviour of ibuprofen during 
wastewater treatment and in surface water. Ibuprofen was found at very high concentrations in 
WWTP influents with a high enantiomeric excess of the pharmacologically active S-enantiomer, 
which significantly decreased as a result of wastewater treatment (Tab. 4). In rivers and lakes, 
ibuprofen was found at much lower concentrations with some excess of the pharmacologically 
active S-enantiomer
90
 (Tab. 5). Winkler et al.
91
 studied ibuprofen in a biofilm reactor with river 
water and observed much higher degradation of non-pharmacologically active R-enantiomer. This 
indicates that the principlal environmental contaminant resulting from the use of ibuprofen is S-
enantiomer, which is pharmacologically active to humans and probably to other vertebrates and 
possibly invertebrates. 
Kasprzyk-Hordern et al.
88
 studied several drugs of abuse such as amphetamines (amphetamine, 
methamphetamine, MDEA, MDMA and MDA), ephedrines (ephedrine, pseudoephedrine and 
norephedrine) and venlafaxine during wastewater treatment. The study of enantiomeric fractions of 
these chiral drugs proved their non-racemic composition (Tab. 4). It was for example observed that 
in the case of methamphetamine, only the more potent S(+)-enantiomer was detected in all treated 
wastewater samples. The opposite situation was observed in the case of amphetamine, where less 
potent R(-)-enantiomer was present in both raw and treated wastewater at slightly higher 
concentrations than S(+)-enantiomer. The study of enantiomeric fractions of MDMA indicated the 
predominance of enantiomer 1 in both raw and treated wastewater samples. However, in the case of 
initially racemic venlafaxine enrichment of this drug with E2-enantiomer was observed as a result 
of wastewater treatment. This again might suggest enantioselective processes occurring. 
In summary, very limited research on enantioselective fate of chiral drugs in the environment has 
been undertaken so far. The available results clearly indicate that enantioselective processes occur 
both during wastewater treatment and in the environment, although more comprehensive research 
has to be undertaken to fully support such a hypothesis. The main difficulty is associated with the 
prediction of stereoselective pathways of chiral pollutants in the environment as this process is 
dependent on the environmental system, the species and the organ. Racemisation and 
enantiomerisation processes can also occur and make interpretation of the data even more 
complex
32
. Enantioselective metabolism patterns in humans and animals to which chiral drugs were 
administered before their excretion into the environment have to be also considered.  
4.2.2. Enantioselective toxicity of chiral drugs in the environment 
Minimal data only exists on enantioselective toxicity of chiral drugs in the environment. Stanley et 
al.
89
 studied enantiospecific effects of fluoxetine on Pimephales promelas (teleost) and Daphnia 
magna (crustacean). S-fluoxetine was found to be more toxic in P. promelas, potentially because its 
primary active metabolite, S-norfluoxetine is more potent than R-fluoxetine in mammals. This was 
not observed for D. magna responses, where both enantiomers revealed similar toxic effects
89
. The 
same group studied enantiospecific toxicity of propranolol
93
. Acute 48h responses of P. promelas 
and D. magna were similar for both enantiomers. Chronic P. promelas responses to propranolol 
revealed higher chronic toxicity of S-propranolol, but chronic D. magna did not follow this 
pattern
93
. 
Lack of toxicological data referring to possible enantioselectivity in toxic responses of aquatic 
organisms in the presence of chiral drugs is surprising and also disturbing. Currently, toxicity of 
chiral drugs towards aquatic organisms is commonly assessed for racemic forms of drugs only (or 
without any specification of which form should be used) and therefore is inaccurate, as it incorrectly 
assumes that enantiomers have identical toxicity. Therefore extensive research is needed here to 
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verify existing ecotoxicological data in the context of chirality of pharmacologically active 
compounds. 
4.3. Chiral drugs of environmental concern 
Below only the most important environmentally relevant groups of chiral drugs will be discussed 
due to constraints regarding manuscript length. Among them are: NSAIDs, analgesics, anaesthetics, 
CNS drugs, cardiovascular drugs, respiratory drugs, gastro-intestinal drugs, antimicrobials and 
chemotherapy drugs. 
4.3.1. NSAIDs, analgesics and anaesthetics 
4.3.1.1. NSAIDs 
NSAIDs are the most widely studied chiral drugs in humans in terms of their stereoselective action. 
Chiral NSAIDs are used as anti-inflammatory, antipyretic and analgesic agents. Among 2-
arylpropionic acids (2-APA) there are: ibuprofen, ketoprofen, fenprofen, flurbiprofen, tiaprofenic 
acid, carprofen, pirprofen, benoxaprofen and naproxen (Fig. 8). Non-APA chiral NSAIDs include: 
etodolac and ketorolac both marketed as racemates
67, 57
 (Fig. 8). Chiral NSAIDs are marketed 
mainly as racemic mixtures although the following NSAIDs: naproxen (marketed only as S-
naproxen), dexibuprofen (chiral switch of ibuprofen) and dexketoprofen (chiral switch of 
ketoprofen) are also distributed as single enantiomers (Tab. 6). 
Several NSAIDs are present in over-the-counter medications and are also prescribed in high 
quantities all over the world. For example ibuprofen is one of the top-ten drugs sold worldwide
94
. 
Annual consumption of ibuprofen in Germany accounted for 345 tonnes in 2001
2
. Annual 
prescription data in England for several chiral NSAIDs is presented in Tab. 6. Racemic ibuprofen 
and S-naproxen were prescribed in 2007 in >100 and >30 tonnes respectively. Ibuprofen is also 
prescribed as single S-enantiomer but at much lower quantities: 0.5 tonne year
-1 19
. Ketoprofen is 
also marketed as both racemate and S-enantiomer. Similarly to ibuprofen, its prescription in 
England as one active enantiomer is much lower than racemate.  
Pharmacodynamics and pharmacokinetics  
NSAIDs act by inhibiting the two isoforms of cyclooxygenase enzyme (COX-1 and COX-2), which 
catalyse the synthesis of different prostaglandins from arachidonic acid. Prostaglandins are involved 
in processes such as inflammation and pain, regulation of blood flow in kidney, coagulation 
processes and synthesis of protective gastric mucosa. Because NSAIDs non-specifically inhibit 
prostaglandin synthesis, most side effects are related to physiological functions of prostaglandins 
and might involve renal and gastric damage. Prostaglandins are also formed in many vertebrates 
and invertebrates; however in lower invertebrates their synthesis involves usage of different 
enzyme. In birds prostaglandins play a role in the biosynthesis of egg shells and therefore COX-
inhibitors (such as indomethacine) can lead to shell thinning
2, 94
.  
Most chiral NSAIDs are extensively metabolised in humans and are excreted mainly as conjugates. 
Metabolic conjugation of drugs with polar molecules such as glucuronic acid is common and should 
be taken into consideration when assessing environmental exposure to these drugs. Unfortunately it 
is rarely reported. In the case of ibuprofen, less than 10% of the administered dose is excreted 
unchanged, 9% of the dose accounts for the 2-hydroxy metabolite (2-[4-(2-hydroxy-2-
methylpropyl)phenyl]propionic acid), 17% accounts for the conjugated 2-hydroxyibuprofen, about 
16% is excreted as the 2-carboxy metabolite (2-[4-(2-carboxypropyl)phenyl]propionic acid) and 
about 19% as the conjugated carboxyibuprofen
96
. Two minor metabolites are also formed: 1- and 3-
hydroxyibuprofen. Both hydroxy and carboxyibuprofen are chiral. However, only in the case of 
carboxyibuprofen and 1- and 3-hydroxyibuprofen the introduction of a second chiral centre in the 
molecule is observed (Fig. 9). Naproxen is excreted mainly as conjugated naproxen (60% of the 
dose), 6-O-desmethylnaproxen (5%) and conjugated desmethylnaproxen (20%). Less than 10% of 
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the excreted material is unchanged drug. Ketoprofen on the other hand is excreted as glucuronide 
conjugate (90%); hydroxylation may also occur
96
. 
Some 2-APA derivatives undergo a unidirectional chiral inversion from the inactive R- to the active 
S-enantiomer (e.g. ibuprofen, ketoprofen and fenoprofen). Chiral NSAIDs are also subject to drug-
dependent stereoselectivity in microsomal oxidation and/or glucuronidation processes. The 
clearances of ibuprofen metabolites are higher for S- than R-enantiomer. Renal clearance of S-
ketoprofen glucuronide is also higher than that of the R-enantiomer. On the other hand, renal 
clearance of tiaprofenic acid and flurbiprofen is not stereoselective and in the case of both drugs 
chiral inversion is very likely to occur. Etodolac shows stereoselectivity in clearance of the 
enantiomers through glucuronidation, with S-enantiomer having 13 times higher value than 
antipode. Ketorolac does not undergo chiral inversion
58,
 
67, 97
. 
2-APA derivatives such as ketoprofen, ibuprofen, naproxen, carprofen, vedaprofen, oxindanac, 
flurbiprofen, fenoprofen are also used in veterinary treatment. Similarly to humans, chiral inversion 
and enantioselective disposition in animals is characteristic for this group of chiral drugs. However, 
it has to be emphasised here that the extent of both processes varies between different species
48, 98
. 
For example fenoprofen has a chiral inversion rate of 90% in dogs, 80% in sheep, 73% in rabbits, 
60% in man, 42% in rats and 38% in horses
48
. Similarly ketoprofen reveals different chiral 
inversion rate in different species: 6% in male sheep (Corriedale), 9% in man, 14% in female sheep 
(Dorset Cross), 15% in goat, 22% in cat, 31.7% in calf and 49% in horse
99
. Tiaprofenic acid also 
shows little chiral inversion in humans but is significant in rats
58
. The phenomenon of metabolic 
inversion has not only pharmacological consequences but also toxicological consequences such as 
formation of hybrid triglycerides and even inhibition of fatty acid β-oxidation100. 
The above discussion indicates that the phenomenon of stereoselectivity of NSAIDs transformation 
is very complex and not uniform for all species, which might significantly complicate research 
efforts aiming to understand the stereoselectivity of these drugs in the environment, their fate and 
toxicity. On the other hand, the above commentary shows that enantioselectivity of NSAIDs is 
crucial in understanding their action and transformation in biological systems. Therefore studies on 
chirality of NSAIDs have to be considered as a vital dimension in environmental research aiming to 
understand their fate in the environment. 
Environmental occurrence and toxicity 
Due to NSAIDs’ high worldwide distribution as human and veterinary pharmaceuticals, their 
widespread occurrence in the environment is to be expected. NSAIDs have an acidic nature and 
pKa values varying from 3 to 5, therefore at neutral conditions they are present in ionised form in 
the environment. As a result NSAIDs have very little tendency to adsorb to sludge and sediments 
but adsorption increases with lower pH. Biodegradation of NSAIDs is believed to be the most 
important factor leading to the removal of these compounds during wastewater treatment. Both 
aerobic and anaerobic processes can take place. The efficiency of their removal during wastewater 
treatment is compound and WWTP dependant and can vary from 0 to 100%
2, 101
. For example in 
Canadian studies of 12 WWTPs, ibuprofen and naproxen were removed with high median reduction 
greater than 93%. Ketoprofen on the other hand was characterised by lower removal at a median of 
44%
102
. Similar results were observed by other research groups
103-107
. Santos et al.
107
 observed 
varying efficiency of ketoprofen and naproxen removal in several WWTPs in Spain accounting for 
38-67% and 40-90% respectively. Ibuprofen removal rates were very high, 88-93%
107
. On the other 
hand Castiglioni et al.
108
 observed season dependant removal efficiencies of ibuprofen accounting 
for 0 to 100% (lower in winter, higher in summer). Kasprzyk-Hordern et al.
9
 reported varying 
removal efficiencies of NSAIDs due to the utilisation of different wastewater treatment processes: 
activated sludge and trickling filters. Activated sludge resulted in a much higher removal efficiency 
of ibuprofen, naproxen and ketoprofen (92, 78 and 74% respectively) than trickling filters (85%, 
58% and 57% respectively)
9
. 
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Biodegradation of NSAIDs also occurs once they are present in the environment but also abiotic 
degradation such as photodegradation (observed for example in the case of naproxen and 
ketoprofen) can take place
109. NSAIDs are frequently detected at high concentrations in the μg L-1 
range in treated wastewater and, as a result of insufficient wastewater treatment, at ng L
-1
, reaching 
at times μg L-1 levels  in surface waters (Fig. 10). NSAIDs such as ibuprofen, ketoprofen and 
naproxen were also quantified in drinking water in France and Finland. Their maximum 
concentrations in drinking water were as follows: 0.6 and 8.5 in the case of ibuprofen, 3 and 8 in the 
case of ketoprofen and 0.2 ng L
-1 
in the case of naproxen
110, 111
. Loraine and Pettigrove
112
 quantified 
ibuprofen in finished drinking water at concentrations ranging from 0.51 to 1.35 μg L-1. It has to be 
however emphasised here that reported levels of NSAIDs in environmental matrices might be 
inaccurate as conjugated or transformation forms of studied drugs are rarely taken into 
consideration. Despite the frequent occurrence of NSAIDs in the environment and significantly 
different pharmacological activity of the enantiomers of chiral NSAIDs, only limited research has 
been undertaken on the enantioselective fate of NSAIDs in the environment and is discussed in 
paragraph 4.2.1. Results of studies undertaken by Buser et al.
90
, Winkler et al.
91
 and Matamoros et 
al.
85
 show that while active S-ibuprofen is more readily metabolised in humans an opposite situation 
is observed in environmental samples. This indicates that the principal environmental contaminant 
resulting from the use of ibuprofen is pharmacologically active to humans and probably to other 
vertebrates and possibly invertebrates S-ibuprofen
91
. Lack of research regarding the enantioselective 
fate of NSAIDs is surprising especially because rather comprehensive knowledge exists concerning 
environmental enantioselective processes for their structural analogues – phenoxyalkanoic acid 
herbicides such as mecoprop and dichlorprop
31
. 
Several studies have been also undertaken for metabolites of NSAIDs but again no enantioselective 
research took place despite the fact that several NSAIDs’ metabolites are chiral. Ibuprofen and its 
metabolites have been studied (without taking into consideration the phenomenon of chirality) by 
several research groups
91, 113-115
. It was observed that microbial biodegradation of ibuprofen leads to 
the formation of the same metabolites as human metabolism. These are: carboxy- and 
hydroxyibuprofen, both chiral molecules. Laboratory studies indicated that both metabolites 
degrade in a river biofilm reactor. However, in human metabolism the metabolite carboxyibuprofen 
appears and degrades second whereas the opposite occurs in biofilm systems
91
. Batt et al.
116
 
quantified 2-hydroxyibuprofen at higher levels than ibuprofen (88-72 ng L
-1
 and 67-200 ng L
-1
 of 
ibuprofen and 2-hydroxyibuprofen respectively) in wastewater effluent samples. Weigel et al.
114
 
observed predominant occurrence of hydroxyibuprofen in WWTP effluents and rivers whereas 
carboxyibuprofen was dominant in seawater samples, which suggests different transformation 
behaviour under freshwater and marine conditions. The above discussion indicates that the 
formation of metabolites is of great importance in understanding the fate of NSAIDs in the 
environment and during wastewater treatment. More importantly, understanding of enantioselective 
behaviour of chiral NSAIDs and formation of their chiral metabolites in the environment is of 
crucial importance in comprehensive and accurate verification of their fate and ecotoxicity, as 
metabolites might reveal equal or even higher toxic effects to their parent molecules. 
NSAIDs were found to have relatively low acute toxicities (EC50 > 100mg L
-1
)
94
, although they 
were found to vary for different NSAIDs and organisms studied. For example acute toxicity of 
naproxen in different organisms vary from 12.3 mg L
-1
 (Cyanobacteria) to 690 mg L
-1
 (O. 
mykiss)
117
. Acute toxicity of ibuprofen is 9.1, 7.1 and 173 mg L
-1
 in the case of daphnid (48h), algae 
(24h) and fish (<96h) respectively. Acute toxicity of naproxen was found to be lower and indicated 
37, 21 and 560 mg L
-1
 in the case of daphnid (48h), algae (24h) and fish (<96h) respectively. In the 
case of ketoprofen acute toxicity for daphnid (48h) was found to be 64 mg L
-1 10
. The above 
discussion indicates that NSAIDs are toxic (EC50 = 1-10 mg L
-1
) or harmful (EC50 = 10-100 mg L
-1
) 
to crustaceans and harmful to fish
3
. Synergistic effects of several NSAIDs and their effect on 
toxicity were also verified. Toxicity of the mixture of a few NSAIDs was found at concentrations 
where single pharmaceuticals showed no or only minimal effects
2
. Higher toxicity of naproxen 
photodegradation by-products to rotifer Brachionus calyciflorus, the water flea Ceriodaphnia dubia 
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and the fairy shrimp Thamnocephalus platyurus than parent compound was also reported
212
. As 
acute toxicity tests do not take into consideration actual long-term environmental exposure to 
NSAIDs at reported environmental levels, their actual potential hazard cannot be underestimated. 
For example chronic toxicity studies indicated that ibuprofen at environmentally relevant 
concentrations (1 and 10 ng/L) is responsible for an activity decrease of freshwater amphipod 
Gammarus pulex
212
. In the case of photosynthetic organisms a five day exposure to ibuprofen at 
concentrations ranging from 1 to 1000 µg/L stimulated the growth of the cyanobacterium 
Synechocystis but inhibited, after seven days, growth of the duckweed plant Lemna minor
212
. 
Unfortunately no research on stereoselective toxicity of NSAIDs has been undertaken to date, 
despite the fact that enantiomers of NSAIDs significantly differ in their activity. As enantiomeric 
composition of chiral drugs is not taken into consideration, ecotoxicity data obtained for racemic 
drugs might lead to under- or overestimation of overall toxicity of the chiral compound and as a 
result indicate the high inaccuracy of currently available toxicological data. This could be the case if 
ibuprofen is taken into consideration. It is observed to be present in the environment with an excess 
of pharmacologically active S-enantiomer, which might reveal higher toxicity towards certain 
organisms than racemic ibuprofen.  
4.3.1.2. Analgesics 
Among chiral analgesics are: morphine, methadone, propoxyphene, tramadol, medetomidine, 
nefopam, eletriptan, zomitriptan, hydromorphone, pentazocine, methylsergide and several others 
(Fig. 8). All reveal enantioselective pharmacokinetics. Naturally occurring opiates (e.g. codeine and 
diamorphine) are distributed in the form of (-)-enantiomer, while synthetic opiates such as tramadol 
are marketed as racemates (Tab. 6). 
Analgesics are distributed worldwide in very high quantities. For example in England only, annual 
prescription of tramadol, codeine and dihydrocodeine in 2008 accounted for 30, 38 and 11 tonnes 
respectively (Tab. 6). Additionally, the usage of analgesics in England reveals a steadily growing 
trend (Tab. 6). 
Pharmacodynamics and pharmacokinetics  
Analgesics are readily metabolised and excreted in the form of conjugates (glucuronide or sulphate) 
or as more polar metabolites. In the case of codeine, 40 to 70% of excreted material accounts for 
free or conjugated codeine, 5-15% free or conjugated morphine, 10-20% free or conjugated 
normorphine. Metabolism of dihydrocodeine includes N-demethylation to form nordihydrocodeine, 
O-demethylation producing dihydromorphine, 6-keto reduction, and conjugation. Diamorphine, 
following injection, is rapidly metabolised to 6-monoacetylmorphine and then more slowly 
metabolised to morphine, which is the major active metabolite. Orally administered diamorphine 
undergoes extensive first-pass metabolism to morphine and is excreted mainly in the form of 
morphine-3-glucuronide and 5-7% of the dose as free morphine, 1% as 6-acetylmorphine
96
.  
Morphine and codeine are used as naturally occurring single (-)-enantiomers with 5 chiral 
centres
118
. The opiate receptors are stereoselective and pharmacological activity is dependant on 
configuration. For example synthetic (+)-morphine has very weak affinity for opiate receptors. 
Metabolism of (+) and (-)-morphine is also stereoselective. 3-O-glucuronide is preferred in the case 
of (-)-morphine, while 6-O-glucuronide is preferred in the case of (+)-enantiomer.  
Tramadol has two chiral centres and as a result four stereoisomers. Clinically it is used as a mixture 
of two enantiomers: 1R,2R(+)-tramadol and 1S,2S(-)-tramadol
57
. (+)-Tramadol and also (+)-
enantiomer of its active O-demethylated metabolite show higher analgesic potency than (-)-
enantiomer
67
. Tramadol is extensively metabolised. The main metabolic reactions are N- and O-
demethylation and conjugation with glucuronic acid and sulphate. The major metabolites formed 
are: O-monodesmethyltramadol, N,O-didesmethyltramadol and their conjugates, and N-
desmethyltramadol. About 30% of a dose is excreted unchanged
96
.  
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Methadone has one chiral centre and is commonly used as racemate
118
. It is metabolised with the 
formation of non-active major 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidone (EDDP, 43% of 
the dose) and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrrolidone (EMDP, 5-10% of the dose). About 
33% of the dose is excreted unchanged
96
. R(-)-enantiomer of methadone is therapeutically active
119
. 
It shows 10 times higher affinity towards μ and κ-receptors and up to 50 times the antinociceptive 
activity than S-enantiomer. Moreover, only R-enantiomer prevents opioid withdrawal syndrome. 
Both enantiomers reveal significant differences in pharmacokinetics. R-methadone shows a 
significantly higher unbound fraction and total renal clearance than S-methadone. Furthermore, 
plasma clearance of the fraction that was not protein bound is significantly lower for R-
methadone
41, 50, 119
.  
Propoxyphene is used as a single enantiomer - dextropropoxyphene
118
. In the case of nefopam, 
which is used as racemate, (+)-enantiomer is 7-30 times more potent than (-)-enantiomer in 5-HT, 
noradrenaline and dopamine binding sites
119
. Medetomidine is widely used in veterinary 
anaesthesia. Anaesthetic potency lies mainly in its D-enantiomer - dexmedetomidine
57
. 
Environmental occurrence and toxicity 
Similarly to NSAIDs, some analgesics are commonly quantified in the aqueous environment at 
levels reaching 100 ng L
-1
 in surface water (Fig. 10) although their occurrence and fate were not as 
extensively studied. Codeine is the most widely studied and found in surface water at high levels 
reaching μg L-1 (Fig. 10). This is due to its high usage and low to moderate removal during 
wastewater treatment. Codeine was found to be removed during WWTP treatment with moderate 
efficiency accounting for 46%±19%
103
. An average of 37±36% and 42±30% removal of codeine 
was observed in the case of trickling filters and activated sludge treatment respectively
9
. Wick et 
al.
120
 reported >80% removal of codeine and morphine as a result of activated sludge treatment. 
However, only limited removal of other opioids (dihydrocodeine, methadone and tramadol) was 
observed
120
.  
Despite the fact that analgesics are readily metabolised and excreted in the form of several 
metabolites, their fate, when taking into account active metabolites was hardly taken into 
consideration. Also, no stereoselective occurrence and fate of these compounds have been reported 
so far. No or very limited environmental toxicity studies have been carried out for this group of 
compounds. Acute toxicity of tramadol was found to be 73 mg L
-1 
for daphnid (48h) and 130 mg L
-1
 
for fish (<96h)
10
, which indicates that this compound is harmful to crustaceans but not toxic to fish. 
Unfortunately, no relevant stereoselective toxicity studies were undertaken. 
4.3.1.3. Anaesthetics 
Several anaesthetics are chiral (approximately 60%) and many are used as racemates. Among 
general anaesthetics are: ketamine, thiopental and also racemic fluorinated agents administered by 
inhalation: halothane, enflurane, isoflurane and desflurane (Fig. 8). Chiral local anaesthetics 
include: bupivacaine, mepivacaine and prilocaine
57, 67
.  
Pharmacodynamics and pharmacokinetics  
Anaesthetics similarly to analgesics are readily metabolised and excreted in the form of conjugates 
or as more polar metabolites. Thiopental is a barbiturate and is widely used in anaesthesia. S-
thiopental is known to be more potent and has a lower safety threshold than R-thiopental. Chiral 
pentobarbital, one of the major metabolites of thiopental, also reveals anaesthetic potency
57, 67
. 
Chiral etomidate is used as R(+)-enantiomer in clinical practice as this enantiomer reveals five 
times higher anaesthetic potency than S(-)-enantiomer
57
. Ketamine is distributed as a racemate (or 
as S(+)-enantiomer in some countries). It reveals stereoselectivity in both pharmacological and 
clinical effects. S(+)-enantiomer reveals higher hypnotic and analgesic potency than R(-)-
ketamine
38, 57
. R(-)-ketamine on the other hand is responsible for side effects in surgical patients 
such as: hallucinations, restlessness and agitation
50
. Ketamine in vivo is demethylated to 
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norketamine, which retains the chiral centre. It is also used in veterinary treatment. Similarly to 
humans, S(+)-ketamine is approximately 3 times more potent than R(-)-ketamine in rats and mice
48
.  
Local anaesthetics prilocaine, mepivacaine and bupivacaine reveal stereoselective 
pharmacokinetics
50
. Both mepivacaine and prilocaine are distributed as racemates. Their 
enantiomers have similar local anaesthetic potency, but they differ in several other aspects resulting 
in S(+)-enantiomers having longer duration of action
121
. S(+)-bupivacaine was also found to have 
similar anaesthetic potency as R(-)-bupivacaine but the latter was found to be more toxic (causing 
cardiac arrhythmias)
67, 122
. Animal toxicity studies have revealed a 50% higher systematic toxicity 
for R-enantiomer attributable to cardiotoxicity and CNS toxicity
123
. Therefore bupivacaine is 
distributed as racemate and also as a single S(-)-enantiomer (levobupivacaine). 
Hyoscine used in anaesthesia, just like other naturally occurring drugs (e.g. morphine, adrenaline, 
noradrenaline and tubocurarine) is synthesised and administered as single stereoisomer. Atropine 
(the racemic form of hyoscyamine) is an exception and is distributed as racemate. Atropine is 
present in plants as an l-isomer but it is converted to a racemic mixture during extraction. As d-
isomer has little or no anticholinergic activity, the overall potency of racemic atropine is reduced in 
50%
121
. 
Environmental occurrence and toxicity 
Limited or no data exists on the occurrence of anaesthetics in the environment and their ecotoxicity. 
No stereoselective studies were undertaken for this group of compounds. Ketamine was the only 
compound studied in environmental matrices and quantified at low ng L
-1 
levels in wastewater 
effluent
6
. 
4.3.2. CNS drugs - psychiatric drugs  
An understanding of the role chirality plays in pharmacology is of crucial importance in psychiatry, 
where the majority of commonly used antidepressants, antipsychotics and benzodiazepines are 
chiral and introduced as racemates. Enantiomers very often reveal different pharmacological effects 
and side effects. 
4.3.2.1. Antipsychotic drugs 
Structures of chiral antipsychotic drugs are presented in Fig. 11. Among them are: thioridazine, 
sulpiride and methotrimeprazine.  
Pharmacodynamics and pharmacokinetics  
Thioridazine is a chiral antipsychotic drug sold as racemic mixture of two enantiomers. 
Thioridazine contains one chiral carbon and is administered as racemate. It is metabolised to two 
sulfoxidated metabolites: 2-sulfoxide thioridazine (mesoridazine) and 5-sulfoxide thioridazine (Fig. 
3), in which a second chiral centre in the form of mono-oxidised sulphur atoms is incorporated. 
Mesoridazine is metabolised further to sulforidazine
67
. Both mesoridazine and sulforidazine are 
pharmacologically active and have been launched as antipsychotics in some countries. 
Thioridazine-2,5-disulfoxide contains three chiral centres. Many of the thioridazine stereoisomeric 
metabolites contribute to the racemate’s pharmacodynamics and cardiovascular toxicity (e.g. 
thioridazine 5-sulfoxide is a cardio-toxic metabolite with four enantiomers)
41
.  
Methotrimeprazine is marketed as a racemate. (-)-Enantiomer reveals higher affinity towards 
dopamine receptors
65
. Sulpiride on the other hand is distributed in some countries as a racemate or 
S-sulpiride in others. S-sulpiride is a more potent antagonist at dopamine D2 receptors than R-
enantiomer
65
. Sulpiride is not metabolised to a great extent
96
. Prochiral risperidone is metabolised in 
liver with the formation of active (equipotent with parent drug) racemic chiral 9-
hydroxyrisperidone
124
.  
Environmental occurrence and toxicity 
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Limited data can be found in literature on the occurrence and ecotoxicity of antipsychotic drugs. 
Sulpiride was quantified at high concentrations exceeding 100 ng L
-1 
in wastewater in China
125
. 
Low removal efficiencies (<40%) of this compound were also observed during conventional 
biological wastewater treatment. However, the application of advanced treatment involving 
ozonation or microfiltration/reverse osmosis resulted in >90% removal of this compound
125
. Acute 
toxicity of thioridazine was found to be high and denoted 4.56 and 0.33 mg L
-1
 in the case of 
daphnid (48h) and fish (<96h) respectively, which indicates that this compound is very toxic to fish 
(EC50 = <1 mg L
-1
) and toxic to crustaceans (EC50 = 1-10 mg L
-1
). In the case of risperidone acute 
toxicity for daphnid (48h) was found to be also high: 6 mg L
-1 10
. Unfortunately, despite common 
usage, no stereoselective studies were undertaken for this group of racemic drugs in the 
environment. 
4.3.2.2. Antidepressants 
Among chiral antidepressants (Fig. 11) are selective serotonin reuptake inhibitors (SSRIs: 
fluoxetine, citalopram, paroxetine, sertraline), serotonin-norepinephrine reuptake inhibitors 
(venlafaxine), norepinephrine reuptake inhibitors (reboxetine), tricyclic antidepressants 
(trimipramine), tetracyclic antidepressants (mirtazapine, mianserin), monoamine oxidase inhibitors 
(tranylcypromine), and several other drugs. Fluoxetine is a commonly prescribed racemic 
antidepressant and is one of the best-selling drugs in the USA. In England its annual prescription 
exceeds 3 tonnes and is steadily growing (Tab. 7). Similarly the annual prescription quantity of 
citalopram (>3 tonnes), sertraline (>4 tonnes) and mirtazapine (>1 tonne) in England rose 
significantly over the recent five years as presented in Tab. 7. Mirtazapine is distributed as a 
racemate and sertraline as one active enantiomer. Citalopram on the other hand is marketed as both 
a racemate and one enantiomer but prescription figures in England (Tab. 7) clearly indicate its main 
usage as racemate. 
Pharmacodynamics and pharmacokinetics  
Metabolism and elimination differ significantly within this group of chiral drugs. However, general 
pattern of significant metabolism leading to the elimination of usually >90% of parent compound 
and formation of several (sometimes active) metabolites can be observed. 
Fluoxetine’s two enantiomers are known to have similar potency in terms of the inhibition of 5-
hydroxytryptamine (5-HT, serotonin) uptake. However, 5-HT uptake inhibition is known to differ 
in the case of the two enantiomers. S-fluoxetine has a higher duration of action than R-fluoxetine 
due to higher potency of its metabolite, norfluoxetine. Chiral norfluoxetine is formed as a result of 
demethylation of fluoxetine. S-norfluoxetine is 15 times more potent than R-norfluoxetine and 1.5 
times more potent than S-fluoxetine
38, 41, 50, 65, 67
. Further metabolism can occur by O-dealkylation 
producing p-trifluoromethylphenol and hippuric acid. Less than 10% of the administered dose is 
excreted as unchanged drug
96
. 
In the case of citalopram, S-enantiomer is characterised by much higher potency in inhibition of 5-
HT uptake. The metabolites of citalopram differ in their pharmacological activity and 
pharmacokinetic profile. Demethylation of citalopram leads to the formation of pharmacologically 
active desmethylcitalopram (S-enantiomer approx. 7 times less potent than the drug). Citalopram is 
distributed as a racemate and S-enantiomer. The single S-enantiomer has been marketed since 2002 
as escitalopram
38, 41, 50, 67
. Metabolism of citalopram is presented in Fig. 12. Only about 12% of a 
daily dose is excreted unchanged in urine
96
. 
Paroxetine and sertraline on the other hand contain two chiral centres and are marketed as single 
stereoisomers. Sertraline isomers reveal selectivity of action. In the case of trans isomers, the (+)-
enantiomer is a potent inhibitor of the uptake of serotonin, dopamine, and noradrenaline and the (-)-
enantiomer is selective towards the inhibition of noradrenaline uptake. In the case of cis isomers, 
(+)-1S,4S-stereoisomer (marketed sertraline) shows potent and selective serotonin uptake inhibition 
activity
38, 126
. Both paroxetine and sertraline (and its main metabolite N-desmethylsertraline) are 
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readily metabolised and excreted mainly in the form of metabolites with <2% of the dose as parent 
compounds
96
. 
Trimipramine is administered as a racemate. Stereoselective metabolism is observed in the case of 
trimipramine with preferential N-demethylation in the case of (+)-trimipramine and 2-hydroxylation 
in the case of (-)-trimipramine
41, 65
 (Fig. 13). Antidepressant activity of trimipramine results from 
(+)-enantiomer. (-)-Enantiomer is considered to be a depressant
126
. 
Mianserin (administered as a racemate) is a chiral tetracyclic antidepressant, in which case S(+)-
enantiomer is pharmacologically active
127
. The main metabolites are: N-desmethylmianserin, 8-
hydroxymianserin (both active) and mianserin N-oxide. Only about 5% of a dose is excreted in 
urine unchanged
96
. 
Mirtazapine is also marketed as a racemate. Both enantiomers reveal different pharmacological 
properties. For example, (+)-enantiomer shows at least 10 times higher affinity for postsynaptic α2-
adrenoceptors. In contrast (-)-enantiomer is 140 times more potent as an inhibitor of the 5-HT 
receptor
41
. Their pharmacokinetics are stereoselective (plasma levels of R(-)-enantiomer are 2-3 
times higher than those of the S(+)-enantiomer)
65
. Metabolism of mirtazapine is also 
stereoselective. R(-)-mirtazapine is metabolised preferentially via N-glucuronidation, whereas S(+)-
enantiomer is preferentially metabolised via 8-hydroxy oxidation, followed by conjugation with 
glucuronic acid
97
. 
Reboxetine on the other hand contains two chiral centres and is marketed as a racemate of only 
RR(-)- and SS(+)-enantiomers. RR(-)-reboxetine is more potent and reveals stereoselective 
difference in plasma protein binding than SS(+)-reboxetine
67
. Rolipram is introduced as racemate. 
R-enantiomer is more pharmacologically potent. Tranylcypromine is another chiral drug 
administered as racemic mixture of 1S,2R(+) and 1R,2S(-)-isomers. Both isomers reveal differences 
in their potency and action. Their pharmacokinetic behaviour is also different
67
. 
Venlafaxine is an inhibitor of reuptake of both serotonin and noradrenaline. It is marketed as a 
racemate. Both enantiomers have antidepressant properties
65
. Venlafaxine undergoes extensive 
first-pass metabolism in the liver, mainly to the active metabolite O-desmethylvenlafaxine. Other 
minor and less active metabolites include: N-desmethylvenlafaxine and N,O-
didesmethylvenlafaxine. Venlafaxine is excreted in urine, in the form of free or conjugated 
metabolites (1-10% unchanged)
96
. 
Amitriptyline is a non-chiral tricyclic antidepressant. It undergoes N-demethylation with the 
formation of the secondary amine nortriptyline (also active). Hydroxylation of amitriptyline and 
nortriptyline is stereo- and enantioselective and leads to the formation of four isomeric alcohols. 
The (-)-E-10-hydroxy-amitriptyline and (-)-E-10-hydroxy-nortriptyline are the major products. 
Their disposition relating for example to glucuronidation is also enantioselective
128, 129
. 
Environmental occurrence and toxicity 
SSRIs including fluoxetine, paroxetine and sertraline are the most commonly used antidepressants. 
As a result they are found in surface water at low ng per litre levels (Fig. 14). There is a risk of 
SSRIs reaching drinking water supplies. For example fluoxetine was quantified in finished water 
samples in the USA at low levels not exceeding 1 ng L
-1 130
. Due to extensive metabolism of SSRIs, 
their metabolites (e.g. norfluoxetine, norsertraline, desmethylcitalopram and nortriptyline) are also 
quantified in environmental matrices at comparable levels to parent compounds
131, 132
 (Fig. 14). 
SSRIs are also known to resist most forms of degradation in the environment and tend to partition 
to sediments, where they might be persistent. Fluoxetine, sertraline, and their metabolites were 
found in fish suggesting possible bioaccumulation potential
2, 94
.   
SSRIs act by inhibiting the re-uptake of serotonin, a neurotransmitter involved in many 
mechanisms: hormonal, neuronal, food intake and sexual behaviour. Serotonin as a neurotransmitter 
exists in lower vertebrates and invertebrates, although, the effects associated with this transmitter 
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are different and possibly the effects of SSRIs can be also different. Serotonin mediates endocrine 
functions in aquatic organisms
2, 94, 133
. Acute and chronic toxicity of SSRIs in aquatic organisms, 
mainly fluoxetine, were studied by several research groups
133-140
. Fluoxetine is the most toxic 
human pharmaceutical reported so far. It’s acute toxicity ranges from EC50 (48h, green alga) = 
0.024mg L
-1
 to LC50 (48h, rainbow trout) = 2mg L
-1 2
. Data on chronic toxicity of SSRIs indicates 
their effect on reproduction of fish and invertebrates
2, 117, 138
. For example out of five SSRIs studied 
(fluoxetine, fluvoxamine, sertraline, paroxetine and citalopram) sertraline was found to be the most 
toxic after 7-8 days of exposure in C. dubia (LOEC=45μg L-1 and NOEC=9μg L-1) but it was also 
confirmed that all five antidepressants could impact on both survival and reproduction
2,141
. 
Fluoxetine was also found to affect the growth and reproduction of freshwater molluscs
133, 139
. 
Nałęcz-Jawecki142 studied toxicity of both fluoxetine and its main metabolite norfluoxetine. Both 
compounds were toxic to applied bioassays with LC50 around 0.5 mg L
-1
. The compounds affected 
the protozoan Spirostomum ambiguum only slightly stronger than the crustacean Thamnocephalus 
platyurus in the 24 h lethality tests. Norfluoxetine was 50% more toxic than fluoxetine in both 
bioassays. The results give a strong indication of the importance of investigation of not only parent 
drugs but also their metabolites
142
. Other antidepressants also revealed high acute toxicity. For 
example, acute toxicity of citalopram was found to be 3.9 mg L
-1 
for daphnid (48h). In the case of 
amitriptyline: 0.78 mg L
-1 
for daphnid (48h) and 0.78 mg L
-1
 for fish (<96h). Studies with 
paroxetine resulted in the following acute toxicity: 0.58 mg L
-1 
for daphnid (48h) and 2 mg L
-1
 for 
fish (<96h). Acute toxicity of sertraline was found to be 0.12 mg L
-1 
for daphnid (48h)
10
. Acute 
toxicity of amitriptyline was found to be 1.15 mg L
-1 
for daphnid (24h)
143
.  
No relevant stereoselective toxicity studies were undertaken for the above mentioned 
antidepressants, with the exception of fluoxetine only. Toxic effects of fluoxetine enantiomers are 
species dependent: S-fluoxetine is more toxic than R-fluoxetine in Pimephales promelas and equal 
toxicity of both enantiomers is observed in the case of Daphnia magna
89
. Up to a 9.4-fold 
difference in toxicity between enantiomers was observed; P. promelas growth EC10s (10% effect 
concentration) for R- and S-fluoxetine were 132.9 and 14.1 μg L-1, respectively. This enantiomer 
dependant toxicity of fluoxetine is of vital environmental importance as fluoxetine is not released to 
the environment in a racemic form. According to limited studies undertaken by MacLeod et al.
84
 
untreated wastewater was found to be enriched with R(-)-fluoxetine, but due to biological 
wastewater treatment the enantiomeric ratio of fluoxetine’s enantiomers changed and resulted in an 
enrichment of fluoxetine with S(-)-enantiomer, which is more potent and toxic to certain organisms. 
It is worth emphasising here that norfluoxetine, the main metabolite of fluoxetine, plays a vital role 
in its potency and possibly toxicity and therefore should always be considered in ecological risk 
assessment of this antidepressant. 
Fluoxetine is only one of many chiral antidepressants which reveal (as discussed above) 
stereoselective potency in humans. There is, based on fluoxetine’s example, a high possibility that 
other chiral racemic antidepressants will also show stereoselective transformation during 
wastewater treatment and/or in the environment, which might subsequently lead to enrichment of 
the drug with a more potent enantiomer and as a result in an increase of its overall toxicity. Primary 
results obtained for venlafaxine during wastewater treatment and published by Kasprzyk-Hordern et 
al.
88
 support this hypothesis. Therefore, especially in the case of chiral antidepressants, distributed 
as racemates and characterised by significant differences in potencies of their enantiomers, 
extensive studies aiming to understand their enantiospecific fate and toxicity should be undertaken. 
As antidepressants are known to be extensively metabolised, the research should involve also their 
active, often chiral metabolites. Among antidepressants of the highest concern are: fluoxetine and 
its main active chiral metabolite norfluoxetine, citalopram and its active chiral metabolite 
desmethylcitalopram, trimipramine, mianserin, mirtazapine, rolipram and several others. Non-chiral 
antidepressants such as amitriptyline should also be considered as their metabolism might lead to 
the formation of chiral metabolites. 
4.3.2.3. Sedative/hypnotics 
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Chiral sedative/hypnotics include: zopiclone, barbiturates (e.g. pentobarbital, hexobarbital, 
mephobarbital) and benzodiazepines (e.g. diazepam, oxazepam and temazepam), which are all 
marketed as racemates (Tab. 7).  
Pharmacodynamics and pharmacokinetics  
Zopiclone (Fig. 11) is a chiral hypnotic agent with stereoselectivity in pharmacokinetics and 
pharmacodynamics. The in vitro affinity of the S(+)-enantiomer for binding to the benzodiazepine 
receptor is 50 times higher than that of R(-)-zopiclone
126
. Its two main metabolites: N-demethylated 
derivative and N-oxide metabolite (active) are also chiral. The enantiomers’ pharmacokinetics 
differs markedly and varies significantly between patients
119
. Only 5% of a dose of zopiclone is 
excreted unchanged in urine and about 16% appears in faeces, the remaining dose is excreted as 
metabolites
96
. 
Barbiturates exert their sedative and anaesthetic effects by potentiating the action of GABA and 
GABAA receptor. Pentobarbital, thiopental and secobarbital, thiamylal, mephobarbital, hexobarbital 
possess one chiral centre and are distributed as racemates. Methohexital on the other hand possesses 
two chiral centres
144
. Hexobarbital and mephobarbital reveal high stereoselectivity in their plasma 
concentrations after racemic doses
67
. Both thiopental and pentobarbital reveal greater volume of 
distribution and higher clearance in the case of R(+)-enantiomer. The S(-)-enantiomers of thiopental 
and pentobarbital are twice as potent as R(-)-enantiomers
144
. 
Benzodiazepines such as diazepam, as well as its metabolites: temazepam and oxazepam are chiral. 
Metabolism of benzodiazepines is stereoselective
126
. Diazepam is metabolised via N-demethylation, 
3-hydroxylation and glucuronic acid conjugation. The major active metabolite of diazepam is 
desmethyldiazepam (nordiazepam); other metabolites include oxazepam and temazepam, both of 
which are active. Only small traces of unchanged diazepam are excreted in urine. Diazepam is a 
metabolite of ketazolam and medazepam. Temazepam is principally metabolised by glucuronic acid 
conjugation; demethylation to oxazepam occurs to a small extent. Less than 2% of the dose in 
excreted unchanged. Oxazepam is excreted mainly in urine as glucuronic acid conjugate with only 
traces of unchanged drug
96
. 
Environmental occurrence and toxicity 
Only a few sedative/hypnotics were the subject of environmental investigation. Among them are 
benzodiazepines such as diazepam and barbiturates such as pento- and hexobarbital. They are 
present in aqueous samples at low ng L
-1
 levels. However, Peschka et al.
145
 quantified barbiturates 
in the river Mulde in Germany at much higher levels reaching 5.4 μg L-1 in the case of pentobarbital 
and 5.3 μg L-1 and 0.1 μg L-1 in the case of butalbital and secobarbital respectively. Diazepam is 
believed to be marginally degraded in surface waters, and due to its relative hydrophobicity 
(logKow, 2.85) and pKa of 3.4, it will partition to river sediments, which suggests its high 
persistence. Oxazepam, on the other hand, due to its higher polarity, will be less likely to persist in 
river sediments
17
. Removal of benzodiazepines during wastewater treatment was reported to be 
limited
120, 146
. Acute toxicities of secobarbital and pentobarbital were found to be: 23.6 mg L
-1 
and
 
49.5 mg L
-1 
for fish (<96h) respectively
10
. Acute toxicity of diazepam denoted 4.3 mg L
-1 
for 
daphnid (24h)
143
. No relevant stereoselective environmental and ecotoxicity studies were 
undertaken for this group of compounds. 
4.3.2.4. CNS stimulants and drugs used for ADHD 
Methylphenidate (ritalin) is a chiral drug used in the treatment of attention deficit hyperactivity 
disorder. (+)-enantiomer is more potent than (-)-enantiomer
67
. (R,R)-Ritalin is used as an anti-
ADHD, while (S,S)-ritalin is used as an antidepressant
147
. In the case of modafinil, an anti-
narcoleptic drug, distributed as a racemate, stereoselective metabolism is observed and the 
clearance of the S(+)-enantiomer is three times higher than R(-)-enantiomer
62
. Annual prescription 
for both modafinil and methylphenidate in England accounts for >0.2 tonnes and is steadily 
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growing
95. To the author’s knowledge no environmental monitoring has been undertaken for these 
compounds to date. 
4.3.2.5. Drugs used in neurological disorders  
There are several chiral anticholinergic drugs used in Parkinson’s disease. These are: procyclidine, 
trihexyphenidyl, biperiden, orphenadrine, ethopropazine, selegiline, levodopa, pergolide, 
apomorphine and entacapone (Fig. 11). Procyclidine, trihexyphenidyl and orphenadrine are 
marketed as racemates. Selegiline, apomorphine and levodopa are marketed as one active 
enantiomer (R(-)-selegiline, R-apomorphine, L-levodopa).  
Among chiral antiepileptics are for example: mephenytoin, ethotoin, ethosuximide, vigabatrin, 
valnoctamide, levetiracetam, tiagabine and entacapone (Fig. 11). Antiepileptics are distributed in 
high quantities. In England annual prescription quantities for racemic ethosuximide and vigabatrin 
exceeds 0.5 and 1 tonne respectively. Levetiracetam marketed as S-enantiomer is annually 
prescribed in England in quantities exceeding 10 tonnes with a growing trend (Tab. 7). 
Pharmacodynamics and pharmacokinetics  
Among drugs used in Parkinsonism, R-procyclidine, R-trihexyphenidyl and (+)-biperiden are more 
potent in their ability to bind to muscarinic receptors. Minimal enantioselective pharmacokinetic 
data exists for this class of chiral drugs
67
. Selegiline (deprenyl) is distributed as R(-)-enantiomer and 
is metabolised to R(-)-methamphetamine and R(-)-amphetamine. Apomorphine is also distributed as 
one R-enantiomer as S-apomorphine is devoid of dopamine agonist activity
144
. Entacapone is a 
geometric isomer and is marketed in the E-isomeric form. It undergoes hepatic glucuronide 
metabolism as well as isomerisation in plasma and red blood cells to the Z-isomer
144
. 
The metabolism of antiepileptic mephenytoin in man is highly stereoselective. S-mephenytoin is 
rapidly metabolised by aromatic hydroxylation to 4-hydroxymephenytoin, which is rapidly 
eliminated in urine as a glucuronide conjugate. R-mephenytoin is metabolised through a different 
pathway, oxidative demethylation to form 5-phenyl-5-ethylhydantoin. Therefore the elimination 
kinetics of the two enantiomers is different. S-enantiomer has half-life of 4h and is eliminated in the 
form of 4-hydroxy metabolite within 24h. On the other hand 5-phenyl-5-ethhylhydantoin has a half-
life of 5-6 days and accumulates as a result of repeated administration and reaches a steady state 
over 2-3 weeks
63
. Phenylethylhydantoin is active and chiral. Both parent drug and metabolite reveal 
high stereoselectivity in the plasma concentrations. However, its level decreases in poor 
metabolizes
67
. Phenytoin is another hydantoin derivative, which although not chiral itself is 
metabolised to chiral 5-(4-hydroxyphenyl)-5-phenylhydantoin, of which R-enantiomer is more 
potent. Similarly chiral ethotoin reveals stereoselectivity in pharmacokinetics
67
. Ethosuximide is 
distributed as a racemate without proven stereoselectivity in pharmacokinetic studies. Chiral 
vigabatrin (administered as racemate) on the other hand reveals high stereoselective 
pharmacokinetic effects and higher pharmacological activity in its S(+)-enantiomeric form
67
. 
Tiagabine is on the other hand distributed as R(-)-enantiomer due to much higher pharmacological 
activity of this enantiomer over S(+)-tiagabine. Levetiracetam is also administered as single S-
enantiomer
144
. Oxcarbazepine, although achiral, is metabolised to active chiral 10-
hydroxycarbazepine that shows stereoselectivity in the plasma concentrations but both its 
enantiomers are known to posses similar antiepileptic activities
67, 144
. Valproic acid (VPA) is also 
achiral, but its structural analogues: 4-yn-VPA and 4-en-VPA are chiral and have varying 
teratogenic potential: R(+)-4-yn-VPA<R(+)-4-en-VPA<VPA<S(-)-4-en-VPA<S(-)-4-yn-VPA. 
Valnoctamide on the other hand is chiral with two chiral centres and as a result four stereoisomers 
with varying pharmacokinetic stereoselectivity
67
. 
Rivastigmine, donepezil and galantamine are chiral drugs used for dementia. Rivastigmine was 
originally introduced as a racemate but later it was marketed as a 10 times more potent S(-)-
enantiomer. In contrast, both enantiomers of donepezil reveal similar potency and therefore this 
drug is marketed as a racemate
144
. 
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Environmental occurrence and toxicity 
Very limited, if any, environmental research was undertaken for chiral drugs used in neurological 
disorders despite the high distribution of some drugs within this group. This is surprising taking into 
consideration the fact that achiral antiepileptics such as carbamazepine or gabapentin were widely 
studied is different environmental matrices. Achiral phenytoin was also studied and quantified in 
wastewater at levels reaching a few hundreds ng L
-1
 and was removed during wastewater treatment 
with only 44% efficiency
106
. Huerta-Fontela et al.
148
 quantified phenytoin in wastewater at similar 
levels but, did not observe any removal of this compound during wastewater treatment. Phenytoin 
was also quantified in raw and finished drinking water at concentrations reaching 5.6 and 2 ng L
-1
 
respectively
149
. Benotti et al.
130
 also quantified phenytoin in several samples of raw, drinking 
finished water and the distribution system in the USA at levels reaching 29, 19 and 16 ng L
-1
 
respectively. Unfortunately, its chiral metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, has 
never been a subject of environmental monitoring. Ecotoxicological studies concerning chiral 
antiepileptics are also limited in scope. Acute toxicity of orphenadrine was for example found to be 
high and accounted for 10.6 mg L
-1 
for daphnid (48h) and 4.3 mg L
-1 
for fish (<96h)
10
. Similarly to 
other groups of chiral drugs no stereoselective studies were undertaken in terms of their occurrence 
in the environment and environmental toxicity. 
4.3.3. Cardiovascular drugs 
4.3.3.1. Beta-adrenoceptor blocking drugs 
Beta-blockers are well understood in terms of their stereoselective pharmacokinetics and 
pharmacodynamics in humans. They posses at least one chiral centre and are characterised by a 
high degree of enantioselectivity to the β-adrenergic receptor. With the exception of timolol 
(marketed as S-enantiomer), they are clinically administered as racemates (Tab. 8). Propranolol, 
metoprolol, esmolol, pindolol and acebutolol with one chiral centre, are marketed as racemate of 
two isomers (Fig. 15). Labetalol with two chiral centres is marketed as a racemate of four isomers. 
Nadolol has three chiral centres
150
. Beta-blockers are widely distributed in the world. Annual 
prescription of several beta-blockers in England accounts for >2 tonnes with atenolol being 
prescribed in the highest quantities exceeding 30 tonnes/year (Tab. 8). In Germany metoprolol was 
consumed in 93 tonnes in 2001 and an increasing trend of consumption has been observed over 
recent years (68 t/1999; 79 t/2000 and 93 t/2001)
2
. 
Pharmacodynamics and pharmacokinetics 
Pharmacological action of beta-blockers (binding with beta-adrenoceptors) in humans is highly 
stereoselective. S(-)-enantiomers reveal much higher cardiac beta-blocking potency than R(+)-
enantiomers in most beta-blockers, with an activity ratio being in the region of S:R = 33 to 530. On 
the other hand R(+)-enantiomers have higher activity in blocking β2 receptors in ciliary processes. 
In the case of sotalol R(-)-enantiomer has much higher beta-blocking activity. Labetalol with two 
chiral centres reveals both beta- and alpha- receptor blocking activity. RR-isomer is responsible for 
beta-blocking activity and SR-isomer is responsible for alpha-blocking activity. On the other hand 
RS- and SS-isomers display weak antagonistic activities against alpha and beta-receptors
150, 151
.  
Stereoselectivity in pharmacokinetics is characteristic for beta-blockers. The elimination of most 
beta-blockers takes place through hepatic metabolism (characteristic for more hydrophobic 
compounds such as propranolol and metoprolol) and/or renal excretion (characteristic for more 
hydrophilic drugs such as atenolol and nadolol, which are excreted, unchanged). Metabolism of 
beta-blockers reveals high stereoselectivity. For example propranolol as shown in Fig. 16, is 
metabolised through three main pathways of glucuronidation, ring hydroxylation and side chain 
oxidation and is selective for less active R(+)-enantiomer resulting therefore in higher plasma 
concentrations of S(-) enantiomer in human. The ring hydroxylation pathway shows selectivity for 
R(+)-propranolol. Formed hydroxypropranolol is further conjugated with glucuronic acid, favouring 
S(-)-enantiomer, or with sulphate favouring R(+)-enantiomer. N-dealkylation favours R(+)-
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enantiomer at low concentrations of propranolol, or S(-)-enantiomer at high concentrations of 
propranolol. Glucuronidation pathway favours S(-)-propranolol
97, 150
.  
Environmental occurrence and toxicity 
Among beta-blockers, propranolol, metoprolol and atenolol are the most widely reported in 
environmental studies concerning pharmacologically active compounds. Due to their high usage, 
they are frequently quantified in surface water at concentrations reaching a few hundreds ng L
-1
 
(Fig. 17). Atenolol was also quantified in several finished drinking water samples in the USA at 
levels reaching 18 ng L
-1 130
. Beta-blockers are removed during wastewater treatment with varying 
low to medium efficiency. For example atenolol removal rate in Italian WWTPs varied form 0 to 
76% and was season dependent
108
. Kasprzyk-Hordern et al.
9
 reported much better efficiency of 
beta-blockers removal during activated sludge treatment (33-81%) when compared with trickling 
filters (0-69%). Atenolol was characterised by the highest removal efficiency as opposed to 
metoprolol and propranolol
9
. Low to moderate beta-blockers removal efficiency during activated 
sludge treatment has been observed by others: 11, 64, 76 and 66% in the case of metoprolol, 
acebutolol, atenolol and sotalol respectively
152
. A similar pattern was observed by Wick et al.
120
. 
Limited enantioselective analysis of beta-blockers in environmental samples was also undertaken 
and is reviewed in paragraph 4.2.1. Several authors reported stereoselective biological degradation 
of beta-blockers during WWTP treatment and in the aqueous environment
79, 82, 83
. Propranolol for 
example has been found to be racemic in wastewater influent. Effluent in contrast was enriched 
with S(-)-propranolol, which is known to have higher toxicity towards Pimephales promelas than its 
antipode
84, 93
.  
Beta-blockers act by competitive inhibition of beta-adrenergic receptors and are used in the 
treatment of high blood pressure and to treat patients after a heart attack. The adrenergic system 
plays a vital part in many physiological functions such as regulation of the heart oxygen need and 
beating, vasodilation mechanisms of blood vessels and bronchodilation. It also interacts with 
carbohydrate and lipid metabolisms, mainly as a response to stress needs such as starvation. Side 
effects of beta-blockers involve bronchoconstriction and disturbed peripheral circulations
2
. Some 
beta-blockers such as propranolol cross the blood-brain barrier
94
. Beta-adrenoceptors are found in 
vertebrates and many invertebrates. Acute toxicity of beta-blockers has not been widely studied, 
although it is known that propranolol is the most toxic. Phytoplankton and zooplankton are more 
sensitive than fish (Ceriodaphnia dubia, EC50(48h)=0.8mg L
-1
; D. magna, EC50(48h)=1.6mg L
-1
; 
Synechococcus leopolensis EC50(96h)=0.67mg L
-1
). As fish contains beta-receptor in heart, liver 
and probably in reproductive tissues, propranolol was found to show chronic toxicity in both the 
cardiovascular and reproductive systems. The lowest-observed-effect-concentration (LOEC) of 
propranolol affecting reproduction in C. dubia was 250 μg L-1. Reproduction was also affected in H. 
azteca at 100 μg L-12, 117. Chronic exposure of D. magna to propranolol (9 days) resulted in a 
significant reduction in heart rate, fecundity and biomass with LOECs values of 55, 110 and 440 
μg/L respectively while chronic exposure to metoprolol showed LOECs of 12.5 mg/L (body mass) 
and 6.15 mg/L (reproduction)
212
. A multigenerational study of Daphnia magna in the presence of 
metoprolol at environmentally relevant concentrations revealed a decreased body length and 
reduced number of offspring
213
. Limited information exists regarding the enantioselective toxicity 
of propranolol as discussed in paragraph 4.2.2.  
4.3.3.2. Anticoagulants 
Among chiral oral anticoagulants marketed as racemates are: warfarin, phenprocoumon and 
acenocoumarol (Fig. 15, Tab. 8).  
Pharmacodynamics and pharmacokinetics  
Warfarin is administered as racemate despite the fact that S(-)-warfarin is more potent
35
. Warfarin 
enantiomers are extensively metabolised by liver. Stereoselective pharmacokinetics is observed in 
the case of this compound. The metabolism of warfarin is qualitatively different. R-warfarin is 
oxidised to 7-hydroxywarfarin and reduced to R,S-warfarin alcohol. S-warfarin (a more active 
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enantiomer with 3-5 times higher anticoagulant potency
50
) on the other hand is oxidised to 7-
hydroxywarfarin and reduced to S,S-warfarin alcohol. S-warfarin can also be metabolised to 6-
hydroxywarfarin. A number of drugs may interact with the metabolism of warfarin enantiomers, 
e.g. sulphaphenazole and tolbutamide are competitive inhibitors of S-warfarin hydroxylation
67
.  
In the case of phenprocoumon, S-enantiomer is 1.5-2.5 times more potent than R-enantiomer
50
. 
Interaction with serum albumin, tissue distribution, as well as pharmacokinetic and 
pharmacodynamic properties of phenprocoumon are also stereoselective
153
. Phenprocoumon is 
excreted almost entirely as a glucuronide conjugate with less than 10% of the dose as unchanged 
drug
96
. 
Environmental occurrence and toxicity 
Warfarin has received minimal attention by environmental research groups. In limited studies 
undertaken it was not quantified in surface water
154
. Acute toxicity of warfarin and warfarin sodium 
salt was found to be 342 and 17 mg L
-1 
for daphnid (48h) respectively and 12 mg L
-1 
for fish 
(<96h)
10
. No stereoselective studies were undertaken for anticoagulants in the environment. 
4.3.3.3. Calcium channel blockers 
The majority of calcium channel blockers are chiral and most of them are distributed as racemates 
(Tab. 8). There are three main groups of calcium channel blockers: dihydropyridines (e.g. 
amlodipine, nircadipine, nimodipine, nisoldipine and felodipine), phenylalkylamines (e.g. 
verapamil) and benzothiazepines (e.g. diltiazem) (Fig. 15)
155
. The annual prescription quantities of 
selected chiral calcium channel blockers in England is presented in Tab. 8. 
Pharmacodynamics and pharmacokinetics  
Many dihydropyridines have one or more chiral centers and are administered as a racemate. 
Enantiomers of dihydropyridines are characterised by different pharmacological and 
pharmacokinetic properties. For example (+)-nicardipine is three times as potent in increasing 
vertebral blood flow and lowering mean blood pressure as the (-)-isomer
155, 156
. The S(+)-
enantiomer of nilvadipine is also about 100 times more potent in relaxing potassium-induced 
contractions of isolated dog coronary arteries than the R(-)-enantiomer
156
. A similar effect is 
observed in the case of amlodipine, where S-enantiomer is potent
151
. Species or sex-dependent 
stereoselective disposition of several dihydropyridines such as: nilvadipine in rats, dogs, and 
humans, felodipine in rats, dogs, and humans, and lemildipine in rats has been also observed, while 
negligible species and sex differences have been found for nisoldipine in dogs, rats, and mice. For 
example S-enantiomer of nilvadipine was more rapidly eliminated in humans, while the opposite 
was true in dogs and rats
155, 156
. 
Verapamil is marketed as a racemate and is used in both human and veterinary treatment. Most of 
the cardiovascular effects of racemic verapamil are mediated by S(-)-enantiomer. S(-)-verapamil has 
more potent vasodilation and cardiac depressant properties. On the other hand R(+)-enantiomer is 
predominantly a vasodilating drug
147
. Clearance and plasma protein binding is stereoselective in 
both humans and animals. Moreover, pharmacokinetics of verapamil is species dependant and can 
be affected by the presence of other drugs
48
. Metabolism of verapamil (Fig. 18) is stereoselective 
and favours the more active S(-)-enantiomer
97, 151, 157
.  
Diltiazem (distributed as cis(+)-stereoisomer), after oral administration undergoes extensive first-
pass hepatic metabolism via deacetylation, N-demethylation, O-demethylation and oxidative 
deamination. Only 2-4% of administered dose appears unchanged in urine
96
. 
Environmental occurrence and toxicity 
No or limited reports exist on the presence of calcium channel blockers in environmental matrices. 
Hummel et al.
146
 reported relatively high concentrations of verapamil in wastewater influent (3.1 μg 
L
-1
), effluent (0.51 μg L-1) and in surface water (6 ng L-1). Acute toxicity of verapamil was found to 
be 7 mg L
-1 
for daphnid (48h) and 6.2 mg L
-1 
for fish (<96h)
10
. Diltiazem was found in surface 
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waters at ng L
-1
 levels reaching 200 ng L
-1
 (Fig. 17). The acute toxicity of diltiazem was reported to 
be 8.2 mg L
-1
 for daphnid (96h)
158
, which indicates that this compound is toxic to daphnid. 
Similarly to other groups of chiral drugs, and despite the fact that most calcium channel blockers 
are distributed as racemates, no stereoselective occurrence and toxicity studies were undertaken for 
this group of compounds. 
4.3.3.4. Anti-arrhythmic drugs 
Many antiarrhythmic drugs are chiral and are distributed as racemates. Among them are: 
disopyramide, encainide, flecainide, mexiletine, propafenone and tocainide (Fig. 15; Tab. 8). These 
drugs are distributed in communities in high quantities accounting in England for >1.5 tonnes/year 
in the case of flecainide. 
Pharmacodynamics and pharmacokinetics  
Antiarrhythmic drugs exert their effects mainly through the blockade of sodium channels. Except 
for flecainide and encainide, significant stereoselectivity in one or more of the pharmacological 
actions of chiral antiarrhythmic drugs (with the activity of one enantiomer 100-fold or higher) can 
be observed. Absorption of antiarrhythmic drugs seems not to be stereoselective but distribution, 
metabolism and renal excretion reveal significant stereoselectivity
157
. For example S(+)-enantiomer 
of disopyramide is much more potent as an antiarrhythmic drug. It is characterised by lower plasma 
and renal clearance than R(-)-enantiomer
147
. In the case of tocainide and mexiletine R(-)-
enantiomers are four and two times respectively more potent than their antipodes in sodium channel 
blocking activity. In the case of propafenone, despite showing no stereoselectivity in sodium 
channel blocking activity, its S(+)-enantiomer is almost 100 times more potent than R(-)-enantiomer 
in the blockage of human β-receptors157.  
Hepatic metabolism plays a major role in the elimination of antiarrhythmic drugs. In the case of 
disopyramide, metabolism is responsible for the elimination of about 45% of administered dose 
with the only identified metabolic pathway being stereoselective mono-N-dealkylation favouring 
S(+)-enantiomer
157
. The major metabolite, N-monodesisopropyldisopyramide, is about one half as 
active as disopyramide. About 50-60% of a dose is excreted in the urine as unchanged drug
96
. The 
elimination of flecainide may account for 60% of administered dose. The major metabolism 
pathways in humans involve the formation of m-O-dealkyl-flecainide and m-O-dealkyl-flecainide 
lactam (Fig. 19). Both pathways might be impaired in poor metabolisers. This inhibition is 
stereoselective and favours R(-)-enantiomer
157
. Metabolism of mexiletine accounting for 90% of 
administered dose is also stereoselective and favours R(-)-enantiomer. The major pathways are 
aliphatic and aromatic hydroxylation leading to hydroxymethyl-mexiletine and m- or p-hydroxy-
mexiletine. A degree of stereoselectivity with the R/S ratio of 11 is observed in the formation of N-
hydroxy-mexiletine glucuronide
157
. In humans, propafenone undergoes extensive metabolism 
(accounting for 100% of administered dose) with the formation of 5-hydroxy- and N-dealkyl-
propafenone as the main metabolites. These two metabolism pathways are not stereoselective. 
Stereoselectivity of propafenone metabolism results therefore from other minor pathways
157
. 60% 
of administered dose of tocainide is eliminated through hepatic stereoselective metabolism leading 
to the formation of a glucuronide conjugate of N-carboxy-tocainide favouring R(-)-enantiomer
157
. 
Environmental occurrence and toxicity 
Limited environmental studies were undertaken for this group of drugs. Furthermore, no research 
concerning their stereoselective toxicity, environmental occurrence and fate has been reported. 
Research efforts should therefore concentrate on understanding the fate of these pharmaceuticals in 
the environment and assessment of their ecotoxicity should be also considered. Due to the common 
formation of active metabolites, their environmental impact should also be estimated. 
4.3.3.5. Other cardiovascular drugs 
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Among chiral angiotensin-converting enzyme (ACE) inhibitors are ramipril, enalapril, lisinopril, 
quinalapril and several others (Fig. 15). ACEs have been developed and are marketed as single 
optical isomers as only S-enantiomer is pharmacologically active
54
. ACEs have been hardly studied 
in the environment. Enalapril is the most commonly reported (Fig. 17). Its removal during WWTP 
treatment accounted for 4-100% and was found to be season dependant
108
. 
Chiral angiotensin II receptor antagonists include: losartan and valsartan
94
 (Fig. 15). Valsartan is 
marketed as a single active S-enantiomer. Losartan’s activity resides only in R-enantiomer159. 
Valsartan was quantified in environmental matrices such as surface water at ppt levels (Fig. 17). 
The acute toxicity of losartan was found to be 331 mg L
-1 
for daphnid (48h), 245 mg L
-1 
for algae 
(24h)  and 929 mg L
-1 
for fish (<96h)
10
.  
There are two types of lipid-regulating drugs: statins and fibrates. They are used to decrease the 
concentration of cholesterol (statins and fibrates) and triglycerides (fibrates) in the blood plasma
2, 94
. 
Statins do not only affect mammals but also interfere with juvenile hormone synthesis in insects and 
also have an adverse effect on algae and plants. Atorvastatin and lovastatin were found to have 
herbicidal activity in duckweed (Lemna gibba) with EC50 of 26 and 33 μg L
-1
 respectively
117
. Both 
acute and chronic toxicity data on this group of compounds is rare
2, 94
. Statins such as: atorvastatin, 
simvastatin, pravastatin, lovastatin and rosuvastatin are marketed as single enantiomers (Tab. 8). 
Their annual usage accounts for tens of tonnes in England. Due to high usage they are quantified in 
environmental samples at ng L
-1 
levels (Fig. 17).  
4.3.4. Respiratory drugs 
4.3.4.1. Bronchodilators  
Bronchodilators open up the airways of the lungs by relaxing the muscles in the air tubes
94
. Among 
chiral β-agonists used in the treatment of asthma are: salbutamol (albuterol), bambuterol, 
isoprenaline, orciprenaline, clenbuterol, formoterol, fenoterol and terbutaline (Fig. 20, Tab. 9). 
Other anti-asthmatic drugs include: zileuton, ipratropium and montelukast (marketed as a single R-
enantiomer). All β-agonists are marketed as racemates despite the fact that R-enantiomers are 
known to be much more potent than S-enantiomers. Trimethoquinol is an exception where S-
enantiomer is more potent
67, 160
. Their metabolism is stereoselective. 
Pharmacodynamics and pharmacokinetics  
Chiral β-agonists are mainly subject to phase 2 metabolism (sulphation and glucuronidation). 
Sulphation is catalysed by a monoamine form of phenol sulphotransferase. S-enantiomers of chiral 
β-agonists reveal much higher affinity towards this enzyme than their eutomers. However, there are 
two exceptions: albuterol and salmeterol, in the case of which R-enantiomer shows higher affinity. 
Enantioselectivity in renal clearance of chiral β-agonists was also reported in the case of albuterol 
and terbutaline. While in the case of albuterol renal clearance is two-fold higher for R-enantiomer, 
the opposite situation is observed in the case of terbutaline
161
. 
Salbutamol is administered as both a racemate and single R-enantiomer. Its bronchodilator activity 
resides in R(-)-enantiomer. S(+)-enantiomer, on the other hand indirectly antagonises the benefits of 
R(-)-salbutamol. Pharmacokinetics is known to be stereoselective in the case of salbutamol. S(+)-
salbutamol is cleared more slowly than its R(-)-enantiomer and therefore the potentially harmful 
enantiomer will be more likely to accumulate. Due to pharmacokinetic and pharmacodynamic 
differences between salbutamol enantiomers a successful racemic switch was undertaken from 
racemic albuterol to R(-)-albuterol (levabuterol)
122, 160, 162, 163
. About 60-90% of an orally 
administered dose is excreted in urine, of which 50% is unchanged salbutamol and 50% is the 4’-O-
sulfate of salbutamol
96
. 
Formoterol has two chiral centres and is introduced as the racemic mixture of active RR- and 
inactive SS-enantiomer. RR-enantiomer is 1000 times more potent at the human β2-adrenoceptor 
than the SS-isomer. SS-isomer, similarly to salbutamol, may be antagonistic to RR-formoterol. In 
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the case of terbutaline, R(+)-isomer has higher activity in β-adrenergic receptor antagonist action164. 
Formoterol is eliminated mainly through glucuronidation, which is stereoselective and favours SS-
isomer
161
. Bambuterol is a prodrug of terbutaline. The drug itself is inactive, but it is metabolized 
enzymatically in vivo by Butyryl Cholinesterase (BuChE) into the active compound terbutaline 
(Fig. 20). R-bambuterol is at least two times more potent than S-bambuterol in the treatment of 
asthma. On the other hand, S-bambuterol was inactive in the treatment of asthma but has more 
adverse cardiac toxic effects than R-bambuterol
165
. Other chiral anti-asthmatic drugs also reveal 
stereoselective metabolism. For example, montelukast undergoes stereoselective oxidative 
biotransformation leading to several isomers. Zileuton also undergoes stereoselective 
glucuronidation at an N-hydroxy group. Zileuton also reveals stereoselective pharmacokinetics, 
with concentrations of the R-enantiomer exceeding those of the antipode
161
. 
Environmental occurrence and toxicity 
Salbutamol is the most widely studied bronchodilator in the environment and quantified in 
environmental aqueous samples across Europe at ng L
-1
 levels reaching 500 ng L
-1 8, 9, 166-169
. Low 
removal efficiencies were observed in Italian WWTPs and accounted for 0-12%
108
. Kasprzyk-
Hordern et al.
9
 observed much higher removal efficiencies of salbutamol accounting for 66% in the 
case of trickling filters and 89% in the case of activated sludge treatment. Jones et al.
170
 also 
observed >90% removal of salbutamol during activated sludge treatment. The acute toxicity of 
salbutamol was found to be 51 mg L
-1 
for daphnid (48h)
10
. Limited enantioselective analysis of 
salbutamol in environmental samples has been undertaken and is reviewed in paragraph 4.2.1. 
Unfortunately, to the author’s knowledge no stereoselective analysis of the ecotoxicity of 
salbutamol has been reported to date. 
4.3.4.2. Antihistamines 
Antihistamines block histamine H1 at the receptor site
94
. Cetirizine (Fig. 20, Tab. 9) is used for the 
treatment of allergic rhinitis (hay fever) and is distributed as a racemate. Levocetirizine (R(-)-
enantiomer) on the other hand is less sedating than the racemate cetirizine
147
. Levocabastine has 
been found to be 4-90 times more potent than dextrocabastine in guinea pigs. Chlorpheniramine is 
available as a racemate. S(+)-enantiomer of chlorpheniramine was found to have higher maximum 
drug levels and lower clearance and volume of distribution. Pyranenamine has two chiral centres. 
SS-isomer was found to have a much more potent inhibitor effect on the allergic response when 
compared with the RR-isomer
164
. Fexofenadine contains one asymmetric carbon and is distributed 
as a racemate. Its enantiomers have equal potencies but different pharmacokinetics e.g. plasma 
concentrations of R(+)-fexofenadine are higher than for S(-)-enantiomer. Clearance of S(-)-
fexofenadine is also significantly higher that R(+)-enantiomer
171. Unfortunately, to the author’s 
knowledge no detailed environmental data on the occurrence and toxicity of antihistamines is 
available. Cetirizine has been recently studied by Huerta-Fontela et al.
148
 in WWTPs. It has been 
found at high concentrations in raw wastewater exceeding μg L-1 levels. In WWTPs effluents it has 
been quantified at levels reaching 500 ng L
-1
.  
4.3.5. Gastro-intestinal system - proton pump inhibitors 
Proton-pump inhibitors inhibit gastric secretion by blocking the H
+
K
+
-ATPase in the proton pump. 
Because the proton pump is the final pathway for the secretion of hydrochloric acid by the parietal 
cells in the stomach, its inhibition dramatically decreases the secretion of hydrochloric acid into the 
stomach and alters gastric pH
94
. Chiral proton pump inhibitors such as omeprazole, pantoprazole, 
rabeprazole and lansoprazole (Fig. 20), which are used in the treatment of gastrointestinal disorders, 
possess a chiral sulphur atom and not carbon. Their metabolism and elimination are 
stereoselective
67, 173
. These drugs are administered as racemates, with the exception of 
esomeprazole, S(-)-enantiomer of omeprazole (Tab. 9). The development of esomeprazole was 
based on the unique metabolic properties of S-enantiomer from racemate. Omeprazole and 
esomeprazole act by blocking the final stage in the acid secretion process. This is done indirectly by 
their metabolite, achiral sulphonamide, which is the actual active inhibitor. Two enantiomers are 
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subject to the same metabolic transformations (Fig. 4) but there are quantitative differences, which 
result in the superiority of S-enantiomer over R-enantiomer or racemate. Hydroxylation is 
responsible for 98% of the total intrinsic clearance of the R-enantiomer and only 70% of S-
enantiomer. Sulphone formation is responsible for 2% of the total intrinsic clearance of the R-
enantiomer and 30% of S-enantiomer. The total intrinsic clearance of S-omeprazole is one-third of 
that of the R-enantiomer in humans. The more advantageous pharmacokinetics for S-omeprazole 
over R-enantiomer or racemate result therefore from the lower metabolic clearance and lower 
variability, which lead to more effective gastric acid inhibition
174
. 
Both the R- and S-enantiomers of lansoprazole are equally pharmacologically potent. However, 
significant differences in pharmacokinetics are observed for the two enantiomers due to 
stereoselective metabolism. Lansoprazole is extensively metabolized in the liver with the formation 
of two major metabolites:  inactive 5-hydroxylansoprazole (chiral, pathway favouring S-
enantiomer) and lansoprazole sulphone (achiral). Because R-lansoprazole is less influenced than S-
enantiomer by metabolism pathway leading to the formation of inactive 5-hydroxylansoprazole, it is 
considered to be the main active compound
173, 175
. Similarly, pantoprazole reveals enantioselective 
pharmacokinetics resulting from enantioselective metabolism. In rats, S-pantoprazole is favoured 
for the formation of pantoprazole sulphone and 6-hydroxy-pantoprazole, whereas R-pantoprazole is 
favoured for the formation of 4’-O-demethyl-pantoprazole sulphide92 (Fig. 21). 
Among proton pump inhibitors omeprazole has received the greatest (although still limited) 
attention in environmental studies
15, 166, 167, 176
. The acute toxicity of omeprazole was found to be 88 
mg L
-1 
for daphnid (48h). The acute toxicity of lansoprazole was found to be 22 mg L
-1 
for daphnid 
(48h) and 18 mg L
-1 
for fish (<96h)
10
. The above mentioned acute toxicity levels indicate that 
proton pump inhibitors can be harmful to aquatic organisms. Additionally, they are expected to be 
present in the environment due to the high usage of these pharmaceuticals worldwide. As presented 
in Tab. 9, these pharmaceuticals are prescribed in tens of tonnes annually in England only. 
Furthermore, despite the introduction of esomeprazole, racemic omeprazole is still being prescribed 
at much higher (ca 4 times) quantities than its chiral analogue (Tab. 9). Research efforts should 
therefore concentrate on this group of chiral drugs, especially because no stereoselective studies on 
environmental fate and ecotoxicity have been undertaken to date. 
4.3.6. Antimicrobials  
Within the group of antimicrobials there are many chiral drugs: antibiotics (e.g. ofloxacin, 
sulfamethoxazole), antifungals (e.g. ketoconazole) (Fig. 20) and antiviral drugs (e.g. valacyclovir). 
There are several fluooroquinolone antibiotics that are chiral and introduced as racemate. These are: 
ofloxacin, tosufloxacin and clinafloxacin. In the case of racemic ofloxacin, only S(-)-enantiomer 
displays a high antibacterial effect against gram-positive and gram-negative organisms (S(-)-
enantiomer, marketed as levofloxacin, is over 100 times more potent than R(+)-enantiomer). 
Furthermore, (+)-enantiomer of tosufloxacin reveals 10 to 100 times higher in vitro level of 
antibacterial activity than its (-)-enantiomer. Low to moderate pharmacokinetic stereoselectivity 
was observed in the case of chiral fluoroquinolones
67
. Semi-synthetic antibiotics manufactured by 
fermentation such as penicillins and cephalosporins are overwhelmingly marketed as single 
isomers
54
. 
Among chiral antimalarials administered as racemate are: primaquine, mefloquine, halofantrine, 
quinacrine, lumefantrine, chloroquine and hydroxychloroquine. Chiral antimalarial drugs reveal 
stereoselectivity in pharmacokinetics and pharmacodynamics and therefore the adverse effects of 
these drugs can be stereoselective. Chiral metabolites are also formed from some chiral antimalarial 
drugs although stereoselective aspects of the pharmacokinetics of the metabolites are not well 
understood
67, 177
. Hydroxychloroquine for example is a racemic drug which is metabolised with the 
formation of three main chiral metabolites: desethylchloroquine, desethylhydroxychloroquine and 
bisdesethylchloroquine. Distribution, elimination and metabolism of hydroxychloroquine are 
enantioselective e.g. renal clearance of S-hydroxychloroquine is higher that R-enantiomer
178
. 
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There are several classes of antifungal drugs. Chiral imidazoles (ketoconazole, econazole, 
bifonazole, fenticonazole, miconazole, isoconazole, tioconazole and sulconazole) and triazoles 
itraconazole and terconazole) constitute an important class. Most imidiazole and triazole antifungals 
are marketed as racemates. Ketoconazole has two chiral centres and is marketed as a racemate of 
cis-configuration ((+)-2R, 4S and (-)-2S, 4R). Pharmacokinetics of ketoconazole is stereoselective 
e.g. enantioselectivity in plasma protein binding is significant
179
. Terconazole, similarly to 
ketoconazole, has two chiral centres and is also administered as a racemic mixture of cis-
configuration. Itraconazole (ITC) has three chiral centres and is marketed as a racemic mixture of 
four stereoisomers in cis-configuration. Its major metabolite, hydroxyitraconazole has four chiral 
centres, is also highly active and can reach levels 2–3 times higher than that of ITC180, 181.  
4.3.7. Antineoplastics 
Cyclophosphamide and ifosfamide (Fig. 20) are commonly used chiral drugs in cancer treatment. 
Their chiral centre is not a carbon atom but phosphorous. In the case of both drugs, not parent 
molecules but their metabolite reveals pharmacological action. This is phosphoramide mustard. 
There is little or no stereoselectivity of cyclophosphamide enantiomers in human plasma, 
metabolism and excretion of cyclophosphamide. On the other hand metabolism of ifosfamide 
enantiomers can have toxicological significance
58, 67
. Ifosfamide is marketed as a racemate and its 
metabolism is enantioselective
178
. Other chiral antineoplastics include: aminoglutethimide (used as 
a racemate in the treatment of breast cancer) and bicalutamide (used in the treatment of prostate 
cancer). (+)-aminoglutethimide reveals higher antitumor activity. Its metabolism and clearance are 
stereoselective. In the case of bicalutamide, R-enantiomer has higher pharmacological activity. 
Similarly to aminoglutethimide, metabolism and elimination are stereoselective with much faster 
clearance of S-enantiomer
67
. 
The acute toxicity of cyclophosphamide was found to be as follows: 70 mg L
-1 
for fish, 1795 mg L
-1 
for daphnid and only 11 mg L
-1
 for algae
3
. Both cyclophosphamide and ifosfamide are non-
biodegradable during wastewater treatment and also when present in the aqueous environment. 
They were detected by Buerge et al.
182
 in untreated and treated wastewater at concentrations of 
<0.3-11 ng L
-1
. In surface waters, concentrations ranged from 50 to 170 pg L
-1
 and were thus 
several orders of magnitude lower than the levels at which acute ecotoxicological effects have been 
reported. However, due to a lack of studies on chronic effects on aquatic organisms and data on 
occurrence and effects of metabolites, a final risk assessment cannot be made
182
 (Buerge et al., 
2006). 
4.3.8. Illicit drugs 
Most illicit drugs are chiral compounds (Fig. 20). Among them are plant-derived substances (e.g. 
cannabis, cocaine and heroin) and synthetic drugs (e.g. amphetamine, methamphetamine and related 
designer drugs). Their enantiomers reveal different potency and are often characterised by 
stereoselective disposition in the body. R,R(+)-LSD is for example over 20 times more psychoactive 
than (-)-LSD
95
. Cocaine, similarly to heroin, naturally occurs in the form of 1R,2R,3S,5S(-)-cocaine. 
(+)-Cocaine (the unnatural enantiomer) is inactive. Both metabolism and toxicity of (+)- and (-)-
cocaine were found to be stereoselective
183
. In cannabinoids, the natural delta-1-THC and delta-6-
THC have a (3R,4R) configuration and a negative rotation. Synthetic (+)-isomers are much less 
active, e.g. (+)-delta-1-THC is ca 13 to 230 times less active than the (-)-isomer in cannabimimetic 
activity
211
. 
Amphetamines belong to the group of central nervous system stimulants. Among them are: 
amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), 3,4-
methylenedioxyamphetamine (MDA) and 3,4-methylenedioxy-N-ethylamphetamine (MDEA). 
Amphetamine and methamphetamine have some limited therapeutic use in narcolepsy and attention 
deficit hyperactivity disorder, but most are manufactured in clandestine laboratories
30
. 
Amphetamine is also formed as a metabolite of methamphetamine and several prescription drugs 
such as selegiline. Amphetamines are characterised by one asymmetric carbon centre and exist in 
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the form of two enantiomers, which significantly differ in potency, e.g. S(+)-amphetamine has twice 
as high stimulant activity than R(-)-amphetamine. However, R(-)-amphetamine has been reported to 
be as effective as the S(+)-enantiomer in the development of the psychotic syndrome. MDMA is 
used as a racemate, although, similarly to amphetamine its S(+)-enantiomer is much more potent as 
a CNS agent than is R(-)-MDMA
95
.  
Environmental occurrence and toxicity 
There are several illicit drugs that have been identified in the aquatic environment. Cocaine and its 
metabolites belong to the group of the most studied illicit drugs in the environment. It is usually 
quantified in surface water at concentrations <50 ng L
-1 
(Fig. 22). Benzoylecgonine, its major 
metabolite, is found in surface water at much higher levels reaching a few hundreds ng L
-1
 (Fig. 22). 
Other metabolites of cocaine quantified in surface waters include: norbenzoylecgonine, norcocaine 
and cocaethylene. Measurable levels of cocaine and its metabolites in surface waters are linked with 
insufficient communal wastewater treatment, as both cocaine and its metabolites are present in raw 
and treated wastewater at high concentrations reaching in the case of benzoylecgonine 10 µg L
-1
 
and 3 µg L
-1
 in wastewater influent and effluent respectively (Fig. 22). Amphetamines, another 
group of central nervous system stimulants, constitute the second group of the most studied illicit 
drugs. Amphetamines are frequently found in rivers across Europe at levels reaching 50 ng L
-1
 (Fig. 
22). Amphetamine is the most abundant drug within the group of amphetamines and is found in 
surface water and wastewater at the highest levels. Concentrations of amphetamines in wastewater 
were found to vary between a few ng L
-1 
and <5 µg L
-1 
in different wastewater treatment plants and 
different countries and are a reflection of local drug abuse trends (Fig. 22). The most abused delta-
9-tetrahydrocannabinol (THC), an active constituent of cannabis, its major metabolite, 11-nor-9-
carboxy-delta-9-tetrahydrocannabinol (THC-COOH) and 11-hydroxy-THC (OH-THC) have also 
been quantified in rivers and/or wastewater at low ng L
-1
 levels (Fig. 22). Other studied illicit drugs 
include: LSD and its metabolites: 2-oxo-3-hydroxy lysergic acid diethylamide (O-H-LSD) and nor-
LSD. This potent hallucinogen has been quantified in wastewater at single ng L
-1
 reaching 3 ng L
-1
 
(Fig. 22).  
Due to very limited data available on the occurrence and fate of illicit drugs in the UK it is very 
difficult to draw any explicit conclusions regarding the possible environmental risk associated with 
the presence of these compounds in the environment. However, the research undertaken clearly 
indicates that illicit drugs as emerging contaminants are omnipresent and persistent in the 
environment. Although they are present in the aquatic environment at low ppt levels, their possible 
effect on living organisms should not be underestimated. This is because illicit drugs reveal very 
high pharmacological potency in humans even when administered at very low levels. For example, 
LSD is among the most potent drugs known, being active in humans at doses from about 20 µg
30
. 
Its possible potency and toxicity in aquatic organisms is not known. Additionally, illicit drugs 
usually occur in the environment simultaneously with other pharmacologically active compounds 
and as a result synergistic action of several active chemicals is to be expected. Communal 
wastewater and its insufficient treatment are considered to be the main source of environmental 
contamination. Therefore more research is needed in order to understand the fate of illicit drugs 
during wastewater treatment and in the environment (both aquatic and terrestrial). In particular, the 
susceptibility of illicit drugs to biological, chemical and physical processes occurring in the 
environment, such as microbial degradation, photodegradation, sorption to sludge particles and soil 
sediments needs to be extensively studied. As several metabolites of illicit drugs are known to be 
pharmacologically active, studies of their occurrence and fate in the environment are of equal 
importance. Studies of the possible acute and chronic toxic effects of illicit drugs on aquatic 
organisms are non-existent and this topic needs urgent attention. The chirality of illicit drugs has to 
be also considered as it is a major parameter determining the potency and toxicity of drugs. The 
preliminary research undertaken by Kasprzyk-Hordern et al.
88
 aiming at enantioselective analysis 
amphetamines (amphetamine, methamphetamine, MDEA, MDMA and MDA) during wastewater 
treatment indicated their non-racemic composition. In the case of methamphetamine, only the more 
 34 
potent S(+)-enantiomer was detected in all treated wastewater samples. The reverse situation was 
observed in the case of amphetamine, where less potent R(-)-enantiomer was present in both raw 
and treated wastewater at slightly higher concentrations than S(+)-enantiomer. The study of 
enantiomeric composition of MDMA during wastewater treatment indicated its enrichment in one 
enantiomer only. This might suggest enantioselective processes occurring during treatment, 
although more comprehensive research has to be undertaken to support such a hypothesis. 
5. Conclusions 
Pharmacologically active compounds constitute a vast and variable group of chemicals. They are 
designed to cause a particular pharmacological action in human or veterinary animals/pets. 
Unfortunately, due to their very often limited metabolism in the body, they are excreted as parent 
compounds and reach wastewater. Here as a result of very often insufficient wastewater treatment 
they reach receiving surface waters with treated wastewater or agricultural fields or landfills with 
sludge. It has to be also remembered that even extensively metabolised pharmaceuticals pose a 
concern as their metabolites might reveal pharmacological potency or toxicity. Despite low ppt 
concentrations of these compounds in environmental matrices, pharmacologically active 
compounds pose considerable environmental concern as many of them are active at very low 
concentrations. Long-term exposure to these compounds has to be also considered. Additionally, 
pharmacologically active compounds are present in the environment as a multi-residue mixture of 
several compounds. Therefore synergistic effects of several compounds should also be considered. 
Due to the non-volatile nature of the majority of pharmacologically active compounds, and their 
continuous introduction into the environment, their possible environmental impact cannot be 
underestimated. Many pharmacologically active compounds are chiral and as a result might reveal 
different environmental persistence, fate and toxicity, which is enantiomeric ratio dependent. 
Unfortunately, the phenomenon of chirality, despite its great importance in the pharmaceutical 
industry has been overlooked by environmental researchers. Currently, environmental fate and 
toxicity of chiral drugs are assessed without taking into consideration their enantiomeric form. This 
might lead to a significant under or overestimation of toxicity of chiral drugs and to incorrect 
environmental risk assessment. Limited research efforts focused on the chirality of drugs in the 
environment have revealed that the removal of certain chiral drugs such as antidepressant fluoxetine 
and beta-blocker propranolol during wastewater treatment and their distribution in the aquatic 
environment are stereoselective. This suggests that certain enantiospecific biological processes, 
with for example preferential degradation of one enantiomer, take place both during wastewater 
treatment utilising biological processes and in the environment. It has to be however remembered 
that changes in enantiomeric fractions of chiral drugs in the environment might also be a 
consequence of changes in enantioselective processes occurring in humans resulting in non racemic 
forms of chiral drugs being excreted. Additionally, enantioselective processes are very complex and 
dependant on the type of organism and chiral compound. As a result studies focused on the 
enantioselective fate of chiral drugs are very challenging to undertake. This does not only concern 
interpretation of data obtained but also analysis of chiral drugs as enantioselective analysis of 
enantiomers of chiral molecules is often problematic.  
As discussed above, the study of the enantioselective fate and toxicity of chiral drugs is of great 
importance and is crucial for a correct risk assessment of the presence of such contaminants in the 
environment. It has been already proven that the phenomenon of chirality is vital in an assessment 
of risk posed by chiral pesticides and other environmental pollutants. Extensive research is also 
needed in the case of chiral drugs, especially those administered as racemates and characterised by 
different pharmacological potency and/or toxicity of their enantiomers. Research efforts should 
especially concentrate on a few major groups of chiral drugs. Among them are: NSAIDs, 
analgesics, CNS drugs (e.g. antidepressants, sedatives, antiepileptics, illicit drugs) and 
cardiovascular drugs (e.g. beta-blockers) as these drugs are distributed in high quantities all over the 
world. Many of them are marketed as racemate and often reveal stereoselective potency and 
metabolism, which might potentially affect their environmental fate and toxicity. Research efforts 
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should additionally also take into consideration metabolites of chiral drugs as many of them are of 
high potency, and possibly toxicity towards certain organisms.  
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Figures 
Fig. 1. Metabolism of warfarin (* - chiral centres; modified from
49
). 
Fig. 2. Metabolism of selegiline (modified from 
184
). 
Fig. 3. Metabolism of thioridazine (modified from
41
). 
Fig. 4. Metabolism of omeprazole (modified from
174
). 
Fig. 5. Metabolism of ibuprofen through chiral inversion (modified from
49, 37, 56
).  
Fig. 6. Introduction of chiral centre as a result of metabolism of achiral drugs (modified from
48, 65, 
66
). 
Fig. 7. Transformation of chiral drugs in the environment 
Fig. 8. Structures of chiral NSAIDs, analgesics and anaesthetics. 
Fig. 9. Major oxidative metabolic pathways of ibuprofen (modified from
185
). 
Fig. 10. Environmental occurrence of chiral drugs – NSAIDs and analgesics (maximum () and 
mean () concentrations)5, 8, 9, 18, 102-105, 107, 110, 111, 154, 166-169, 186-198. 
Fig. 11. Structures of chiral CNS drugs.  
Fig. 12. Metabolism of citalopram (modified from
41
). 
Fig. 13. Metabolism of trimipramine (modified from
41
). 
Fig. 14. Environmental occurrence of chiral drugs – CNS drugs (maximum () and mean () 
concentrations)
8, 9, 25, 106, 116, 120, 125, 130-132, 146, 148, 169, 176, 186, 188, 189, 192, 199-204
. 
Fig. 15. Structures of chiral cardiovascular drugs. 
Fig. 16. Stereoselective metabolism of propranolol (modified from
150
). 
Fig. 17. Environmental occurrence of chiral drugs – cardiovascular drugs (maximum () and mean 
() concentrations)8, 9, 15, 18, 116, 130, 148, 152, 167, 186, 187, 192, 199, 203-207. 
Fig. 18. Metabolism of verapamil (modified from
157
). 
Fig. 19. Metabolism of flecainide (modified from
157
). 
Fig. 20. Structures of other chiral drugs. 
Fig. 21. Metabolism of pantoprazole (modified from
92
)  
Fig. 22. Environmental occurrence of chiral drugs – illicit drugs (maximum () and mean () 
concentrations)
5-9, 21-28, 146, 198, 208-210
. 
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Table 1. New synthetic drugs launched in the world in years 1985-2004
43
. 
Year Racemates [%] Single enantiomers [%] Achiral [%] 
1983 37 26 37 
1984 28 26 46 
1985 38 22 40 
1986 26 26 48 
1987 18 49 33 
1988 26 39 35 
1989 29 26 45 
1990 33 35 32 
1991 20 40 40 
1992 21 44 35 
1993 16 45 39 
1994 38 38 24 
1995 21 46 33 
1996 9 41 50 
1997 24 30 46 
1998 15 50 35 
1999 13 52 35 
2000 9 62 29 
2001 0 68 32 
2002 6 55 39 
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Table. 2. Racemic switches for chiral drugs
38, 39, 43, 46, 122
. 
Chiral drug 
(racemate) 
Enantiomer  Action of single 
enantiomer 
Status 
Fenfluramine Dexfenfluramine 
S(+)-Fenfluramine 
Anorectic Launched as single enantiomer in US 
(1996); withdrawn in 1997 
Ofloxacin Levofloxacin 
S(-)-Ofloxacin 
Antibacterial Sold as single enantiomer in JP 
(1995) 
Labetalol Dilevalol Beta-blocker Withdrawn 
Ibuprofen Dexibuprofen 
S(+)-Ibuprofen 
Anti-inflammatory Launched as single enantiomer in 
Austria (1994) 
Ketoprofen Dexketoprofen 
S(+)-Dexketoprofen 
Anti-inflammatory Launched as single enantiomer in EU 
(1998) 
Bupivacaine Levobupivacaine 
S(-)-Bupivacaine 
Local anaesthetic Launched as single enantiomer in US 
(2000) 
Ketamine S-Ketamine Anaesthetic Sold as single enantiomer in 
Germany 
Fluoxetine S-Fluoxetine Antidepressant Development stopped 
Omeprazole Esomeprazole 
S(-)-Omeprazole 
Proton-pump 
inhibitor 
Launched as single enantiomer in EU 
(2000) 
Salbutamol 
(albuterol) 
R(-)-Salbutamol 
(R(-)-Albuterol) 
Anti-asthmatic Launched as single enantiomer in the 
US (1999) 
Cetirizine Levocetirizine 
R(-)-Cetrizine 
Allergy, 
antihistamine 
Launched as single enantiomer in EU 
(2001) 
Methylphenidate 
((R,R)(+), (S,S)(-)) 
Dexmethylphenidate 
(R,R)(+)-
Methylphenidate 
Attention-deficit 
hyperactivity disorder 
Launched as single enantiomer in US 
(2001) 
Citalopram Escitalopram 
S(+)-citalopram 
SSRI Launched as single enantiomer in EU 
(2001) 
Zopiclone Eszopiclone Hipnotic Launched as single enantiomer 
(2004) 
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Table 3. Enantioselective analysis of chiral drugs in environmental matrix. 
Chiral drugs Resolution Chromatographic conditions Reference 
Atenolol 
Metoprolol 
Propranolol 
 
0.8 
0.7 
0.9 
Direct chiral LC/MS/MS 
Sample preparation: SPE (Oasis HLB);  
LC/MS/MS: Chirobiotic V vancomycin-based 
chiral column; mobile phase: 90/10 H2O/MeOH, 
TEA, CH3COOH (pH=4)  
79 
Atenolol 
Metoprolol 
Propranolol 
Pindolol 
Nadolol 
Sotalol 
Citalopram 
Fluoxetine 
Β2-agonist: 
Sabutamol 
1.15 
1.10 
1.32 
0.99 
0.70 
1.34 
1.06 
1.88 
 
0.98 
Direct chiral LC/MS/MS 
Sample preparation: SPE (Oasis HLB);  
LC/MS/MS: Chirobiotic V vancomycin-based 
chiral column; mobile phase: 90/10 H2O/MeOH, 
TEA, NH4OAc, HCOOH (pH=4) 
MQL, 1-24 ng L
-1 
(wastewater) 
84 
Propranolol 
Metoprolol 
 
- Indirect chiral GC/MS/MS 
Sample preparation: SPE (C18); derivatisation 
with MSTFA and (-)-MPTA-Cl 
LOD, 0.1-1 ng L
-1 
(surface water and wastewater) 
83 
Ibuprofen 
Naproxen 
- Direct chiral GC/MS 
Sample preparation: SPE (Strata X) 
GC/MS: Astec Chiraldex dimethyl β-cyclodextrin 
chiral column 
85 
Ibuprofen 
Carboxy-ibuprofen 
Hydroxy-ibuprofen 
- Direct chiral GC/MS 
Sample preparation: SPE (Bio-Beads SM-2, 
polystyrene divinylbenzene copolymer) 
GC/MS: OV1701-DMPen (DMPen = 
heptakis(2,6,-O-dimethyl-3-O-n-pentyl)-β-
cyclodextrin) 
90 
Amphetamine 
Methamphetamine 
MDEA 
MDMA 
MDA 
Ephedrine/Pseudoephedrine 
Norephedrine 
Venlafaxine 
2.2 
1.2 
1.2 
3.2 
4.0 
3.6 
1.1 
1.1 
Direct chiral LC/MS/MS 
Sample preparation: SPE (Oasis HLB);  
LC/MS/MS: Chiral CBH column; mobile phase: 
90/10 H2O/2-propanol, 1mM ammonium acetate 
(pH=5) 
88 
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Table 4. Enantiomer fractions (EF) of chiral drugs and enantiomer enrichment during wastewater 
treatment 
Drug WWTP: treatment Wastewater influent Wastewater effluent Reference 
  Conc 
[ng L
-1
] 
EF  Conc 
[ng L
-1
] 
EF   
Propranolol 
 
 
Atenolol 
 
 
Metoprolol 
WWTP1 (Aug): biological, UV 
WWTP1 (Nov): biological, UV 
WWTP2 (Sep): aeration 
WWTP1 (Aug): biological, UV 
WWTP1 (Nov): biological, UV 
WWTP2 (Sep): aeration 
WWTP1 (Aug): biological, UV 
WWTP1 (Nov): biological, UV 
WWTP2 (Sep): aeration 
~100 
0 
~10 
~650 
~1100 
~800 
~550 
~400 
~310 
~0.47
1 
- 
- 
~0.48
1 
~0.49
1 
~0.39
1 
~0.41
2 
~0.54
2 
~0.60
2 
Racemic 
- 
- 
Racemic 
Racemic 
S(-)>R(+) 
Racemic 
Racemic 
E1>E2 
~100 
~20 
~5 
~780 
~600 
~180 
~400 
~400 
~180 
~0.37
1 
~0.45
1 
~0.38
1 
~0.42
1 
~0.48
1 
~0.46
1 
~0.53
2 
~0.5
2 
~0.45
2 
S(-)>R(+) 
Racemic 
S(-)>R(+) 
S(-)>R(+) 
Racemic 
Racemic 
Racemic 
Racemic 
E1<E2 
79 
Atenolol 
Propranolol 
Fluoxetine 
Metoprolol 
Nadolol 
Sotalol 
Citalopram 
Sabutamol 
WWTP1: biological, UV 
 
971 
10 
18 
411 
51 
529 
307 
20 
~0.53
1 
~0.5
1 
~0.2
1 
~0.52
2 
~0.69
2 
~0.56
2 
~0.57
2 
~0.39
2 
R(+)>S(-) 
Racemic 
S(+)<R(-) 
E1>E2 
E1>E2 
E1>E2 
E1>E2 
E1<E2 
664 
45 
14 
375 
20 
466 
207 
17 
~0.50
1 
~0.42
1 
~0.3
1 
~0.52
2 
~0.79
2 
~0.56
2 
~0.63
2 
~0.40
2 
Racemic 
S(+)<R(-) 
S(+)<R(-) 
E1>E2 
E1>E2 
E1>E2 
E1>E2 
E1<E2 
84 
Propranolol WWTP1 (Apr): activated sludge 
WWTP1 (Sep): activated sludge 
WWTP2 (Apr): activated sludge 
WWTP2 (Sep): activated sludge 
WWTP3 (May): trickling filter 
WWTP4 (Jun): activated sludge 
WWTP5 (Jun): activated sludge 
WWTP6 (Jun): activated sludge 
WWTP7 (Jul): activated sludge  
23 
13 
250 
- 
58 
- 
- 
22 
- 
0.50
1 
0.50
1 
0.49
1 
- 
0.54
1 
- 
- 
0.52
1 
- 
R(+)=S(-) 
R(+)=S(-) 
R(+)=S(-) 
- 
R(+)>S(-) 
- 
- 
R(+)>S(-) 
13 
11 
58 
21 
3 
10 
9 
53 
160 
0.44
1 
0.42
1 
0.41
1 
0.40
1 
0.33
1 
0.37
1 
0.30
1 
0.33
1 
0.31
1 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
R(+)<S(-) 
83 
Ibuprofen 
Naproxen 
WWTP1: activated sludge  0.88
3 
0.88
3 
S>R 
S>R 
 0.64
3 
0.86
3 
S>R 
S>R 
85 
Ibuprofen WWTP1 (Oct) 
WWTP1 (Nov) 
WWTP1 (Dec) 
WWTP2 (Feb) 
WWTP3 (Feb) 
3300 
990 
2900 
1360 
2040 
6.2
4 
5.7
4 
8.0
4 
7.9
4 
5.5
4 
S>R 
S>R 
S>R 
S>R 
S>R 
~2 
- 
~2 
13 
81 
~1.5
4 
- 
~2
4 
0.9
4 
1.0
4 
S>R 
 
S>R 
S<R  
S=R 
90 
Amphetamine 
 
 
 
Venlafaxine 
WWTP1 
WWTP2 
WWTP3 
WWTP4 
WWTP1 
WWTP2 
WWTP3 
WWTP4 
368.1 
63.7 
73.6 
181.7 
226.3 
630.3 
156.5 
113.9 
0.58
2 
0.62
2 
0.54
2 
0.68
2 
0.50
2 
0.45
2 
0.46 
0.50 
R(-)>S(+) 
R(-)>S(+) 
R(-)>S(+) 
R(-)>S(+) 
E1=E2 
E1<E2 
E1<E2 
E1=E2 
- 
- 
- 
- 
265.6 
426.5 
239.9 
217.2 
- 
- 
- 
- 
0.43
2 
0.42
2 
0.48
2 
0.37
2 
- 
- 
- 
- 
E1<E2 
E1<E2 
E1<E2 
E1<E2 
88 
1
 - EF = (+)/[(+)+(-)] where (+) and (-) are peak areas of the (+) and (-) enantiomers 
2
 - EF = E1/[E1+E2] where E1 and E2 are peak areas of the first and second-eluted enantiomers 
3
 - EF=S/(R/S+R) where S and R are peak areas of the S and R enantiomers 
4
 - ER=S/R where S and R are peak areas of the S and R enantiomers 
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Table 5. Enantiomer fractions (EF) of chiral drugs in surface water. 
Drug River Conc  
[ng L
-1
] 
EF   Reference 
Metoprolol Trinity River, Texas (travel time, ~0 days) 
                                                     ~4 
                                                     ~8 
                                                     ~11 
                                                     ~13.5 
~390 
~340 
~180 
~90 
~40 
~0.45
1 
~0.44
1 
~0.41
1 
~0.38
1 
~0.31
1 
 82 
Ibuprofen Greifenesee (outlet) (Aug) 
Greifenesee (outlet) (Sep) 
Greifenesee (outlet) (Dec) 
Greifenesee (outlet) (Mar) 
Greifenesee (outlet) (Apr) 
Greifenesee (outlet) (May) 
Greifenesee (outlet) (Jul) 
Greifenesee (outlet) (Aug) 
Greifenesee (outlet) (Dec) 
Aabach Tributary (Aug-Oct) 
Pfäffikersee (Aug) 
Zürichsee (Dec-Oct) 
Baldeggrersee (Jun-Nov) 
Sempachersee (Aug-Jul) 
4.3 
4.7 
7.8 
4.3 
7.8 
2.0 
5.2 
5.2 
4.7 
<0.2-2.4 
4.0 
3.3-4.0 
1.5-3.2 
<0.2 
~0.7
2 
~1.0
2 
2.0
2 
2.1
2 
2.0
2 
1.6
2 
1.6
2 
1.1
2 
1.8
2 
0.9-3.0
2 
1.4
2 
1.0
2 
1.3
2 
1.8-4.1
2 
S<R 
S=R 
S>R 
S>R 
S>R 
S>R 
S>R 
S>R 
S>R 
S<R-S>R 
S>R 
S=R 
S>R 
S>R 
90 
1
 EF = (+)/[(+)+(-)] where (+) and (-) are peak areas of the (+) and (-) enantiomers 
2
 ER=S/R where S and R are peak areas of the S and R enantiomers 
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Table 6. Prescription of chiral drugs in England – selected chiral NSAIDS and analgesics 
(approximate values)
19
. 
Chiral drug Marketed as Prescription [tonnes year
-1
] 
  2004 2005 2006 2007 2008 
NSAIDs: 
Etodolac Racemate 4.8 7.4 7.5 7.0 6.4 
Ibuprofen 
Dexibuprofen 
Racemate 
S-enantiomer 
~129 
0 
~131 
0.05 
~121 
0.5 
~117 
0.5 
~119 
0.4 
Ketoprofen 
Dexketoprofen 
Racemate 
S-enantiomer 
0.8 
0.03 
0.7 
0.02 
0.6 
0.02 
0.5 
0.01 
0.5 
0.01 
Naproxen S-enantiomer 26.2 29.2 29.3 32.0 43.5 
Analgesics: 
Methadone  Racemate and R-enantiomer 1.0 1.2 1.4 1.6 1.8 
Tramadol 2 isomers: 1R,2R(+), 1S,2S(-) 17.0 20.5 23.9 26.9 30.0 
Codeine (-)-enantiomer 25.2 24.3 30.2 35.2 37.9 
Dihydrocodeine  (-)-enantiomer 10.9 11.4 11.3 11.2 11.0 
Morphine  (-)-enantiomer 2.6 2.9 3.3 2.3 - 
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Table 7. Prescription of chiral drugs in England – selected chiral CNS drugs (approximate 
values)
19
. 
Chiral drug Marketed as Prescription [tonnes year
-1
] 
  2004 2005 2006 2007 2008 
Antidepressants: 
Fluoxetine Racemate 3.6 3.6 3.8 4.1 4.2 
Citalopram  
Escitalopram 
Racemate 
S-enantiomer 
3.0 
0.4 
3.3 
0.5 
4.0 
0.6 
5.0 
0.5 
5.9 
0.5 
Paroxetine  Single-enantiomer 1.9 1.6 1.5 1.4 1.3 
Sertraline 1S,4S(+)-enantiomer 4.2 4.2 4.4 4.8 5.2 
Trimipramine Racemate 0.4 0.3 0.3 0.3 0.3 
Venlafaxine Racemate 10.3 9.0 7.7 7.7 8.2 
Mirtazapine  Racemate 0.9 1.1 1.3 1.6 1.8 
Bupropion Racemate 1.1 1.1 1.0 1.0 0.5 
Sedative/hypnotics: 
Zopiclone Racemate 0.7 0.6 0.6 0.7 0.7 
Diazepam Racemate 0.7 0.7 0.7 0.7 0.7 
Oxazepam Racemate 0.1 0.1 0.1 0.1 0.1 
Temazepam Racemate 1.5 1.5 1.3 1.2 1.1 
Antiepileptics: 
Ethosuximide Racemic 0.7 0.7 0.6 0.6 0.6 
Vigabatrin  Racemic 1.4 1.3 1.2 1.1 1.0 
Levetiracetam S-enantiomer 10.2 12.8 15.7 19.0 21.2 
Entacapone E-isomer 1.8 2.3 2.7 3.2 3.6 
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 Table 8. Prescription of chiral drugs in England – selected chiral cardiovascular drugs 
(approximate values)
19
. 
Chiral drug Marketed as Prescription [tonnes year
-1
] 
2004 2005 2006 2007 2008 
Beta-blockers: 
Atenolol Racemate 42.2 41.6 37.7 32.3 30.1 
Labetalol Racemate 2.0 1.9 1.8 1.7 1.7 
Metoprolol  Racemate 3.0 3.1 3.0 3.0 2.9 
Propranolol Racemate 8.0 7.9 7.7 7.6 7.7 
Sotalol Racemate 3.5 3.4 3.4 3.4 3.3 
Anticoagulants: 
Warfarin Racemate 0.7 0.8 0.8 0.9 0.9 
Calcium channel blockers: 
Verapamil Racemate 8.0 7.2 7.1 7.0 6.8 
Diltiazem Cis (+)-stereoisomer 24.1 24.3 24.3 24.4 24.4 
Felodipine Racemate 0.7 0.8 0.9 1.0 1.0 
Amlodipine Racemate 2.3 2.5 3.0 3.5 3.9 
Anti-arrhythmic drugs: 
Disopyramide Racemate 0.6 0.6 0.5 0.5 0.4 
Flecainide  Racemate 1.5 1.5 1.6 1.7 1.7 
Mexiletine  Racemate 0.1 0.1 0.1 0.1 0.09 
Propafenone  Racemate 0.5 0.5 0.5 0.5 0.5 
Angiotensin-Converting Enzyme Inhibitors: 
Ramipril S-enantiomer 2.1 2.5 2.9 3.5 4.0 
Enalapril  S-enantiomer 2.0 2.0 1.9 1.8 1.8 
Lisinopril S-enantiomer 3.4 3.6 3.9 4.1 4.6 
Angiotensin-II Receptor Antagonists: 
Valsartan S-enantiomer 5.7 6.8 7.7 8.2 8.3 
Losartan R-enantiomer 6.9 7.9 8.6 8.8 8.9 
Lipid regulating drugs: 
Atorvastatin Single-enantiomer 8.0 10.1 11.1 10.6 10.7 
Simvastatin Single-enantiomer 12.3 16.8 24.3 33.1 39.0 
Pravastatin  Single-enantiomer 2.6 2.3 2.1 1.9 1.9 
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Table 9. Prescription of chiral drugs in England - respiratory and gastro-intestinal drugs 
(approximate values)
19
. 
Chiral drug Marketed as Prescription [tonnes year
-1
] 
2004 2005 2006 2007 2008 
Bronchodilators (β2-agonists):  
Salbutamol Racemate 0.3 0.3 0.2 0.1 0.2 
Terbutaline Racemate 0.03 0.03 0.02 0.01 0.008 
Bambuterol Racemate 0.006 0.005 0.005 0.004 0.003 
Antihistamines: 
Cetirizine 
Levocetirizine 
Racemate 
R(-)-enantiomer 
0.9 
0.07 
0.8 
0.08 
0.9 
0.08 
1.0 
0.06 
1.2 
0.05 
Fexofenadine Racemate 4.8 5.0 - 5.7 6.2 
Proton pump inhibitors:  
Omeprazole 
Esomeprasole 
Racemate 
S(-)-enantiomer 
3.8 
1.2 
5.5 
1.4 
7.3 
1.6 
8.9 
2.1 
10.8 
1.6 
Pantoprazole  Racemate 1.0 1.1 1.1 0.9 0.7 
Lansoprazole Racemate 7.7 7.8 8.2 9.7 10.8 
 
 
 
